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I Introduction 
 
I.1 Chronic inflammatory diseases – a social and economic burden 
The demographic transition towards an overall older population is expected to continue 
into the future, resulting in more people suffering from age-associated disorders. Following 
this tendency, the ratio of care-dependent people to care assistants is anticipated to increase 
significantly. As a result, the economic burden on public health systems will become 
devastating. In addition to cardiovascular diseases and cancer, disorders caused by chronic 
inflammation are also widespread age-related diseases. Among several skin diseases and 
chronic wounds, such as atopic dermatitis, diabetic ulcers and psoriasis, the term “chronic 
inflammatory diseases” covers a long list of diverse disorders including arthritis, 
rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE), 
and inflammatory bowel disease (IBD). The most recent US data on the incidence of RA, 
for example, are from the Rochester Epidemiology Project, which found that from 1995 to 
2007, 41 per 100,000 people were diagnosed with RA each year. Most importantly, the 
incidence rose with age (e.g. 8.7 per 100,000 people among those aged 18-34 compared to 
89 per 100,000 people aged 65-74 years) [1]. Another critical aspect is represented by 
disease-associated direct and indirect costs. A study of direct (i.e. medical) costs in the 
Rochester Epidemiology Project found that people with RA were approximately six times 
more likely to incur medical charges than people without arthritis [2]. An older study also 
found that indirect and non-medical expenditure for RA patients was almost three-fold 
higher compared to people without arthritis (US$ 2269 versus US$ 816) [3]. These 
statistics emphasize that RA, and chronic inflammatory diseases in general, not only 
represent a social but also an economic burden for the society.  
Despite their own specific triggers, symptoms and clinical characteristics, the common 
underlying mechanism of pathogenesis in these diseases is the impaired ability to resolve 
inflammation, which may be caused by external pathogens, irritants or tissue damage, or 
by endogenous signals such as apoptotic or necrotic events. The initial inflammation phase 
is characterized by an invasion of monocytic cells, such as neutrophils and macrophages, 
which produce pro-inflammatory cytokines and subsequently recruit essential effector cells 
to the site of infection or injury. These include keratinocytes and fibroblasts that promote 
healing and cause the healing process to enter the final phases of new tissue formation and 
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tissue remodeling [4]. The dwell time of macrophages producing soluble mediators is 
therefore known to be critical [5, 6]. The persistence of macrophages during the initial 
inflammatory phase has been shown to arrest the wound-healing process resulting in non-
resolving inflammation [7, 8]. This dysregulation of macrophages has been observed in 
several chronic skin diseases. The persistence of macrophages in human patients with 
chronic venous ulcers is known to cause DNA damage and defective tissue repair mediated 
by reactive oxygen species (ROS) [9]. Another chronic skin disease with an increasing 
prevalence is atopic dermatitis, affecting 10–20% of children and 1–3% of adults in 
industrial countries [10, 11]. In addition to its significant influence on the health of affected 
individuals, the economic impact of atopic dermatitis is estimated to be billions of dollars 
[12]. The development of atopic dermatitis has been associated with chronic inflammation 
and the dysregulated accumulation of macrophages [13, 14]. Furthermore, there is strong 
evidence that the same process occurs in SLE and diabetic wounds, both of which are also 
chronic skin diseases that cannot yet be treated effectively [7, 8, 15]. 
Targeting macrophages during chronic inflammation could therefore represent a 
promising intervention strategy to correct the imbalance between pro-inflammatory and 
anti-inflammatory cytokines and to promote the successful resolution of chronic 
inflammation. 
 
I.2 Current treatment options 
To date, no specific targets exist for most inflammatory diseases. Current therapies rely 
primarily on facilitative and symptomatic rather than curative approaches. The treatment of 
RA, for example, consists of blocking the effect of tumor necrosis factor (TNF)-α, a pro-
inflammatory cytokine secreted by activated inflammatory macrophage and Th1 cells, 
using monoclonal antibodies (mAbs) such as infliximab®, etanercept® or adalimumab® 
[16]. Mesalamine (5-aminosalicyl acid) is another anti-inflammatory drug that is routinely 
used for treatment of IBD, including ulcerative colitis and Crohn’s disease [17, 18].  
However, clinical management through the blocking of pro-inflammatory cytokines 
targets the amplification loop of inflammation by depleting secondary inflammatory 
signals (e.g. TNF-α) rather than intervening in the initiation cycle (Figure 1). Furthermore, 
the depletion of antigen-specific T cell subsets is associated with an undesirable reduction 
of immune system diversity. Interventions that target the cause of the imbalance between 
pro- and anti-inflammatory cytokines rather than the amplification cycle would potentially 
result in a more rational approach to suppress chronic inflammation. Suitable targets 
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include macrophages that substantially contribute to chronicity by producing pro-
inflammatory soluble mediators. 
 
 
Figure 1. Initiation and amplification of an inflammatory response. 
Abbreviations: MHC, major histocompatibility complex; NKR, natural killer cell receptor; MΦ, 
macrophage; NK, natural killer cell; Th0, undifferentiated T helper cell; Th1, differentiated T helper cell. 
 
 
I.3 The role of macrophages in the immune system 
Macrophages belong to the mononuclear phagocytic system and are present in virtually all 
tissues. They originate from hematopoietic stem cells in bone marrow, which develop into 
circulating monocytes followed by regulated migration into different steady state or 
inflamed tissues, where they finally differentiate into tissue-specific macrophages [19]. 
The nomenclature of terminally-differentiated macrophages includes among others 
osteoclasts in bone marrow, microglial cells in the central nervous system, alveolar 
macrophages in lungs, Kupffer cells in the liver, and various forms of spleen macrophages 
[20]. These strongly-phagocytic cells have long been considered to play a key role in the 
immune system. For the very first description of phagocytosis and its importance in 
immunity, Metchnikoff was awarded with the Nobel prize in 1908 [20, 21]. This discovery 
has inspired immunologists to explore the function of macrophages as immune effector 
cells and to broaden the understanding of how these cells participate directly in host 
defense. Over time, their original function of pathogenic and homeostatic clearance, which 
includes the essential recycling of iron by the engulfment of erythrocytes, and the removal 
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of cell debris derived from tissue remodeling, apoptosis and necrosis, has been extended to 
more complex physiological processes [20, 22-24]. It is now recognized that they are 
potent inducers and regulators of immune responses and play a central role in the 
orchestration of many metabolic functions in health and disease. Inflammation is one of the 
conditions in which macrophages play a critical role. The release of cytokines from 
neutrophils, which are the first cells to infiltrate sites of inflammation [25], subsequently 
leads to the recruitment of macrophages which then guide the course of inflammation until 
resolution is achieved. In wound healing for instance, macrophages participate in all three 
major phases comprising inflammation, new tissue formation and tissue remodeling by 
communicating with keratinocytes [26-28], fibroblasts and myofibroblasts [29-31], and 
endothelial cells [32-34]. For this reason, macrophages play a key role in the maintenance 
of physiologically-normal inflammation. The pathology and proper resolution of 
inflammation are therefore closely related in terms of macrophage-coordinated events. 
 
I.4 Polarization of macrophages 
Inflammation is a complex and dynamic physiological process, which requires well-
balanced and controlled interactions among diverse cells. Macrophages are critically 
involved in both the initiation and resolution of inflammation. Spanning the different 
phases of an inflammatory response to infections or skin damage, their functions include 
the production of pro-inflammatory cytokines and cytotoxic compounds, the secretion of 
various growth factors to promote the function of other cells contributing to the resolution 
of inflammation, fighting invading microbes, and scavenging cell debris. These factors are 
produced at different times by different types of macrophages.  
Several recent reports have made clear that “the” macrophage does not exist, but that 
the term macrophage refers to a population of versatile cells that share some common 
denominators. Macrophages are thus considered as plastic and flexible cells reflecting their 
ability to adapt to a changing cytokine milieu and to influence the milieu by producing an 
array of soluble mediators [35]. The acquisition of diverse functional phenotypes in 
response to environmental cues is reflected in the classification of polarized rather than 
activated macrophages.  
Mirroring the Th1/Th2 dichotomy, polarized macrophages were subdivided into M1 and 
M2 types. M1 polarization, also referred to as classical activation, follows stimulation with 
interferon-γ (IFN-γ) released from innate and adaptive immune cells, alone or in concert 
with bacterial lipopolysaccharide (LPS) [36]. In response to stress or an initial encounter 
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with pathogens, natural killer (NK) cells produce IFN-γ as part of the innate immune 
system, thus polarizing macrophages to M1. As well as a greater capacity for antigen 
presentation [37, 38], these M1 cells are characterized by enhanced microbicidal and 
tumoricidal activity mediated by the increased production of superoxide anions and oxygen 
and nitrogen radicals, which confers direct host resistance to infections [39-41]. However, 
the ability of NK cells to provide sustainable amounts of IFN-γ is limited. Since M1 
macrophages induce a Th1 response by secreting high levels of pro-inflammatory 
cytokines such as IL-12, IL-23 and TNF-α, the polarization of macrophages to M1 can be 
amplified by a continual supply of IFN-γ from T cells. In contrast to T cells, which act in 
an antigen-specific manner, M1 polarized macrophages kill non-specifically, and are 
merely restricted by the distance to the target cell.  
M1 macrophages represent one extreme of polarization, whereas the second extreme is 
achieved by alternatively-activated macrophages or M2 macrophages [23]. During the past 
decade, this term has been expanded to include a more heterogeneous cell population [42, 
43]. The nomenclature of alternatively-activated macrophages is somewhat confusing and 
changes over time, often including the terms M2, alternatively-activated macrophages, 
type II activated macrophages, deactivated macrophages, M2a, M2b, M2c and others. In an 
effort to develop a clearer and more informative classification for polarized macrophages, 
Mosser and Edwards [20] suggested the following three sub-populations based on their 
functions: host defense, wound healing and immune regulation. This classification is in 
accordance with that proposed by Mantovani et al. [37], where M1 would refer to host 
defense, M2a to wound healing and M2b/M2c to immune regulation. For the 
discrimination of different macrophage phenotypes, Mantovani et al. not only considered 
the function, but also the stimuli generating the corresponding subpopulations. Thus, M2a 
is produced by IL-4 or IL-13, both of which activate STAT6 by binding to the IL-4 α-
subunit common to both receptors [44-46]; M2b results from combined exposure to 
immune complexes with Toll-like receptor (TLR) or IL-1 receptor (IL1R) ligands; and 
M2c is induced by IL-10 [37]. Extending the Mosser and Edwards classification, 
Mantovani et al. also discriminate between M2b macrophages, which in addition to 
immunoregulatory functions also induce Th2-driven inflammation, and M2c macrophages, 
which are thought to be predominantly responsible for negative/deactivating 
immunoregulation. More recently, additional sub-populations of macrophages were 
discovered (Figure 2). 
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Figure 2. Different polarized MΦ populations. 
Abbreviations: MΦ, macrophage; IC, immune complex; TLR, Toll-like receptor; IL-1R, IL-1 receptor; 
Ox-PL-PPC, ox-PL 1-palmitoyl-2arachidonoyl-sn-glycero-3-phosphorylcholine; HH-complexes, hapto-
hemoglobin; oxRBC, oxidized red blood cells; CSF, colony stimulating factor; CXCL4, chemokine (C-
X-C motif) ligand 4. 
 
Despite their use as a control population during in vitro experiments, the existence of 
M0 macrophages in vivo is doubtful. Another population of macrophages expressing a 
unique set of genes (including heme oxygenase-1/HO-1, sufiredoxin-1 and thioredoxin-
reductase) in a manner dependent on Nrf2 (nuclear factor [erythroid-derived 2-like] 2) was 
found in the context of atherosclerosis within the aortas of 30-week-old western diet-fed 
Ldlr−/− mice by immunohistochemistry (IHC) and flow cytometry. In vitro, this phenotype 
could be induced by ox-PL 1-palmitoyl- 2arachidonoyl-sn-glycero-3-phosphorylcholine, 
resulting in their designation as Mox macrophages [47]. Furthermore, Mox macrophages 
seem to be closely related to the recently proposed hemorrhage-associated macrophages 
(Mha) [48, 49]. Human monocytes can be differentiated into Mha macrophages in vitro 
using hapto-hemoglobin complexes or oxidized red blood cells, leading to the upregulation 
of CD163, HO-1 and IL-10 in an Nrf2-dependent manner. Furthermore, a CSF/CXCL4-
dependent macrophage subset termed M4 was discovered in 2010 [50]. These 
macrophages were shown to be characterized by a mixed but unique profile of transcripts, 
including higher levels of CD86 and TNF-α (both M1-like), CD206, CCL18 and CCL20 
(all M2-like) and lower levels of pentraxin 3 (PTX3), CD36 and IL-10 (M2-like). 
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Although these M4 cells have weak phagocytic activity, their function remains poorly 
understood. Finally, the laboratory of Samuel Joseph Leibovich has characterized one 
further M2 subtype termed M2d, which unlike previously-described M2-like macrophages 
are the result of a switching event from M1 macrophages in response to adenosine A2A 
receptor signaling induced by TLR agonists [51]. M2d macrophages were shown to 
strongly inhibit the expression of pro-inflammatory cytokines including IL-12 and TNF-α, 
while producing high levels of IL-10 and vascular endothelial growth factor (VEGF). 
Interestingly, the classical markers of wound healing and M2a macrophages were not 
upregulated, suggesting M2d and M2c macrophages have a similar phenotype. The 
phenotypes of the different polarized macrophages are summarized in Figure 3. 
 
 
Figure 3. Phenotypes of different polarized macrophages.  
Polarized macrophages show characteristic expression profiles of surface receptors and soluble 
mediators. M1 macrophages are characterized by an elevated expression of the co-stimulatory receptors 
for T cell activation CD80 and CD86 and both MHC molecules underlining their role as potent antigen 
presenting cells. On the soluble level, M1 macrophages upregulate the expression and secretion of pro-
inflammatory cytokines such as IL-12, IL-6 and TNF-α. In contrast, M2(a-d) macrophages preferentially 
produce anti-inflammatory cytokines (e.g. IL-10). Another hallmark of M2 macrophages (especially 
M2a and M2c) is the upregulation of the mannose receptor (CD206). Recently identified macrophage 
subsets (M4, Mox and Mha) remain poorly characterized. Abbreviations: MΦ, macrophage; MHCI/II, 
major histocompatibility complex I/II; SLAM, signaling lymphocytic activation molecule; RNI, reactive 
nitrogen intermediates; ROI, reactive oxygen intermediates; iNOS, inducible nitric oxide synthase; 
RELM-α, resistin-like molecule α; YM1, heparin binding lectin; Arg, arginase; TGF-β, tumor growth 
factor β; PTX3, pentraxin 3; VEGF, vascular endothelial growth factor; CCL18/20, chemokine (C-C 
motif) ligand 18/20; HO-1, heme oxygenase-1 (HO-1); SD-1, sulfiredoxin-1; TR-reductase, thioredoxin-
reductase. 
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The immense diversity of polarized macrophages illustrates how different physiological 
processes might be regulated accurately by distinct macrophage subsets depending on the 
environmental conditions. As already indicated for M2d, all polarization subsets are also 
believed to be plastic and to undergo phenotypic and functional switches in response to 
signals from the milieu, thus making the versatility of the macrophage system even greater 
than permitted from the initial polarizing stimulus. However, the imbalance and/or 
dysregulation of macrophage-controlled processes are strongly associated with 
pathological outcomes including several autoimmune diseases, impaired wound healing, 
metabolic disorders, and cancer [9, 15, 52-57]. Certain macrophage subsets maintain the 
cytokine milieu sustainably by secreting autocrine factors, leading to the persistence of 
these cells for an inappropriate period of time. In addition, T cells become activated and 
promote the inflammatory status even further. Both cell types, T cells and macrophages, 
are initiators of different inflammatory diseases and can be used as targets for diagnosis 
and therapy. Based on recently-acquired knowledge concerning the involvement of distinct 
polarized macrophages in certain diseases and the anticipated rapid increase of novel 
findings in this field, polarized macrophages are attracting great interest in the research 
community. The targeted depletion of distinct macrophage populations without adversely 
affecting others would allow selective therapy with fewer side effects. However, the 
polarization of macrophages is a new field of research and little is presently known about 
the origin, function and plasticity of different polarized macrophages. Thus far, there are 
no effective therapies selectively targeting one population of macrophages. 
 
I.5 Plasticity of polarized macrophages – M1 vs. M2 
The plasticity and flexibility of the activation state are key features of macrophages [20, 
22, 58]. In tissues, macrophages respond to environmental signals derived from microbes, 
damaged tissues and activated lymphocytes such as T or NK cells, and acquire a distinct 
phenotypic and functional profile [22, 35]. IFN-γ, which is initially provided by NK cells, 
acts in concert with LPS to induce M1 polarization [24]. While the action of IFN-γ is 
coordinated through STAT1, the effect of LPS is conveyed by TLR4 signaling, which 
involves the NF-κB pathway and interferon regulatory transcription factor 3 (IRF-3). Both 
pathways induce the transcription of genes encoding pro-inflammatory mediators, such as 
IL-12, TNF-α and NOS2. In turn, these cytokines induce a Th1 response, which further 
promotes the existence of M1 macrophages [35, 59]. In contrast, IL-4-induced M2 
polarization counteracts the effect of IRF-3 and activates STAT6, which promotes the 
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transcription of genes encoding anti-inflammatory proteins including Arg1, PPARγ, Fizz1, 
SOCS1 and KLF4. SOCS1 and KLF4 are involved in the feedback inhibition of STAT1 
and the NF-κB pathway, respectively [60-62]. The spectrum of polarized macrophage 
phenotypes includes not only M1 and M2, but any possible intermediate phenotype 
because the acquisition of a distinct phenotype is not rigid but dynamic and flexible. 
Therefore, both M1 and M2 macrophages can be re-polarized by appropriate stimuli in 
vitro and in vivo [63, 64]. This process is particularly common when either type of 
polarized macrophage is associated with pathology. Dynamic changes from M1 to M2 
often correlate with chronic bacterial infections, whereas chronic inflammatory diseases 
often involve the accumulation of M1 (see IV.1). However, it remains unclear whether the 
predominance of one of the macrophage populations results from switching events in situ 
or from the recruitment of new monocytes from the circulation.  
Intriguingly, the terms flexibility and plasticity have recently been applied to T cells. 
Th1, Th2 and regulatory T cells (Tregs) cells were also shown to display macrophage-like 
plasticity [65]. A transition from protective Th2 to pathogenic Th1 cells was observed 
during the development of diet-induced obesity. Indeed, the depletion of Th1 cells by 
treatment with an anti-CD3 antibody and the reintroduction of Th2 cells redirected both the 
T cell and macrophage profiles to the alternative phenotype seen in lean animals [66-68]. 
Nevertheless, the phenotypic changes of T lymphocytes are more or less restricted by 
chromatin modifications following exposure to polarizing cytokines [20, 69]. Conversely, 
macrophages do not get “locked” into a stable polarization state but instead show a 
transient functional pattern. Depending on the type, concentration and the duration of 
exposure to the stimulus, this pattern can be altered, weakened or reversed to the basal 
state. The response of already-stimulated macrophages towards another polarizing cytokine 
strongly depends on the chronological order and synergistic or antagonistic effects among 
the added cytokines. For instance, it has been shown that macrophages pre-incubated with 
IL-4 overnight prior to stimulation with LPS produce high levels of M1-associated soluble 
markers, such as IL-12 and TNF-α. In contrast, if macrophages are double-stimulated with 
IL-4 and LPS, only low levels of IL-12 and TNF-α are produced [70, 71]. The remarkable 
plasticity of human macrophages has been demonstrated in response to IL-33, a member of 
the IL-1 family that is known to enhance Th2 responses. The characterization of its effect 
on primary human macrophages revealed that IL-33 promotes M1 polarization in naïve 
macrophages but enhances the production of M2 markers in already-polarized cells 
irrespective of the prior polarization state [72]. 
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I.6 CD64 (FcγRI) as a target 
CD64 is the only high-affinity Fcγ receptor (FcγR) in humans. It binds human IgG1, IgG3 
and IgG4 with high affinity but has no affinity for IgG2 [73]. In addition to high-affinity 
binding, CD64 displays several unique properties compared to the other three FcγRs: 
FcγRII (CD32), FcγRIII (CD16) and neonatal FcγR). These are (1) the ability to bind and 
internalize monomeric IgG [74]; and (2) constitutive expression solely on macrophages, 
monocytes and their progenitors [75-78]. Although FcγRs are expressed on both human 
and mouse immune cells, there are significant differences between these receptors. 
Whereas CD64, CD32B and CD16A are present in both species, CD32A, CD32C and 
CD16B are found only in humans. In contrast, the recently-identified FcγRIV is found only 
in mice [78]. Since the nomenclature of these receptors is based on amino acid sequence 
homology and does not necessarily reflect functional properties or similar expression 
patterns in each species, the role of human FcγRs may not be predicted from the role of 
their homologs studied in mice [79]. To circumvent these species-dependent differences, 
transgenic mice expressing human FcγRs have been generated to enable their analysis in 
disease and therapy models in vivo [80, 81]. The upregulation of CD64 has been reported 
in several chronic diseases, especially in the skin of atopic dermatitis patients during the 
chronic phase [82]. Transgenic mice expressing human CD64 (hCD64) allow the direct 
testing of human drugs in vivo and have therefore been repeatedly used as therapy models 
[83].  
There is strong evidence that the inappropriate persistence of M1 macrophages during 
the course of inflammation leads to the development and perpetuation of many chronic 
inflammatory and autoimmune diseases. Although it is beneficial to eliminate activated 
macrophages in arthritis, chronic inflammation and in models of chronic cutaneous 
inflammation, the underlying mechanism has not been characterized [83-88]. This thesis 
describes the use of human CD64-transgenic (hCD64tg) mice to selectively target the M1 
population of macrophages. 
 
I.7 CD64-targeted immunotoxins  
Classical immunotoxins (ITs) comprise a binding domain and a toxic domain, optionally 
separated by an adapter peptide. The binding domain can be a ligand (e.g. a growth factor), 
an antibody or a derivative thereof (e.g. a scFv or Fab). The optional adapter peptide is 
used to improve the efficiency of translocation from the endosome into the cytosol. 
Naturally-occurring adapter sequences can be derived from Pseudomonas exotoxin A 
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(ETA), which includes a binding domain, a translocation domain and a toxic domain. 
Alternatively, synthetic adapters containing an endosomal cleavable peptide, a membrane 
transfer peptide and a cytosolic cleavable peptide can be engineered. For cytotoxicity, 
bacterial toxins (e.g., ETA, diphtheria toxin), plant-derived toxins (e.g., ricin), or human 
enzymes (e.g., granzyme B, angiogenin) can be used (Figure 4). 
 
 
Figure 4. Basic architecture of ITs. 
Abbreviations: Ag, antigen; Ab, antibody; Fab, fragment antigen binding; scFv: single chain fragment 
variable; ETA, Pseudomonas exotoxin A; B, Binding domain; A, translocation domain; T, toxic domain; 
ECP, endosomal cleavable peptide; MTP, membrane transfer peptide; CCP, cytosolic cleavable peptide; 
DT, diphtheria toxin; Ang, angiogenin; Gb, granzyme B. 
 
After binding of the antibody to a target cell antigen, the IT is internalized followed by 
endosomal processing and final release of the mature toxin into the cytosol, where it 
induces cell death. Ligands such as interleukins and growth factors have also been used as 
targeting components [89-93]. The internalization is exclusively dependent on the binding 
moiety and can vary strongly. In contrast, translocation to the cytosol can depend on 
several factors including the nature of the toxic domain, the design of the fusion protein 
(e.g. the presence of translocation-supporting peptide sequences between the binding and 
toxic domains), and the presence of a C-terminal endoplasmic reticulum (ER)-retention 
signal [94-96].  
In the context of macrophages, the first evidence for successful targeting using hCD64 
was provided by Thepen et al. in 2000, when they eliminated hCD64-positive macrophages 
using the IT H22-RicinA thus resolving chronic skin inflammation in transgenic mice 
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within 24 h [85]. In addition, these authors showed by histological examination that other 
inflammatory cells disappeared from the site of inflammation, and clinical parameters such 
as vascular leakage and physiological temperature were restored. Six years later, the same 
group inhibited the progression of arthritis in a rat model and efficiently killed activated 
macrophages from synovial fluid obtained from human rheumatoid arthritis patients using 
the same IT [87]. The therapeutic approach of targeting macrophages using H22(scFv)-
ETA' was then transferred to an ischemia-reperfusion rat model, where Fet et al. showed 
that treatment with H22(scFv)-ETA' [84] could preserve renal function and morphology 
and ameliorate ischemia-induced kidney injury. Although the elimination of activated 
macrophages was effective for the treatment of inflammatory diseases, this strategy needs 
to be considered with caution in the context of other macrophage-associated diseases. For 
example, during pulmonary tuberculosis in mice, macrophages were shown to have a dual 
function. Therefore, although non-specific depletion of all macrophages using liposomes 
improved the clinical outcome, the specific elimination of activated macrophages impaired 
resistance to infection, reflected by enhanced mycobacterial outgrowth [97]. This study 
confirms the existence of distinct macrophage populations, each fulfilling different 
functions. It is therefore important to ensure the specific and selective targeting of specific 
macrophage populations without adversely affecting other, potentially favorable, sub-
populations.  
Finally, the successful application of H22-RicinA and H22(scFv)-ETA' in different 
therapeutic approaches (not only the inflammatory diseases described above, but also 
cancer) has promoted the development of ITs that do not contain potentially immunogenic 
plant-derived or bacterial toxins, i.e. a new generation of ITs also known as fully human 
cytolytic fusion proteins (CFPs). 
 
I.8 Human cytotoxic proteins as an alternative to bacterial toxins 
One of the criteria for an effective IT toxic domain is the ability to induce apoptosis rather 
than necrosis or pyroptosis, as this is a strongly regulated form of cell death that does not 
affect the local environment [98]. The most prominent toxins which have been used thus 
far are ricin from plants, especially the A chain, bacterial ETA, and diphtheria toxin [99]. 
Whereas ricin A prevents the association between elongation factor (EF) 1/2 and the 60S 
ribosomal subunit [100, 101], the bacterial toxins inhibit protein synthesis by 
enzymatically catalyzing the adenosine diphosphate ribosylation of EF2 in the cytosol 
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[102, 103]. Historically, due to their relatively strong side effects, ITs have only been used 
in life-threatening diseases and were therefore restricted to indications such as cancer.  
Recently, Madhumthi and Verma reviewed current therapeutic targets for 
immunotherapy emphasizing that cancers, including solid tumors, lymphoma and 
leukemia, represent the dominating indication for classical ITs [104]. In addition to their 
toxic side effects, the immunogenicity of chimeric ITs comprising a murine or human 
antibody and a bacterial or plant toxin is also regarded as an obstacle for treatment [105] 
because neutralizing antibodies generated by the immune system would reduce the number 
of possible treatment cycles. Attempts to reduce immunogenicity include the removal of 
potential T- and B-cell epitopes on ETA [106-108] and the modification of ITs using 
polyethylene glycol, which reduces the immunogenicity of interferon and L-asparaginase 
[109-111], although these strategies have failed to make a significant impact. Vascular leak 
syndrome triggered by the binding of toxins to endothelial cells is another disadvantage of 
chimeric ITs. This has been addressed by receptor mutation, and the use of anti-
inflammatory agents or inhibitors preventing binding to endothelial cells [110]. Low or 
non-killing concentrations of such ITs have also been reported to induce an enhanced 
inflammatory response by the activation of innate immune sensors [112-114]. This is 
particularly relevant in the context of treating inflammatory diseases as it would counteract 
the desired effect of resolving inflammation.  
A far more promising approach is the development of fully human CFPs, comprising a 
fully human targeting unit fused to a human pro-apoptotic protein. More than 10 such 
proteins have been identified and their improved safety profile is gaining attention. These 
include RNases (e.g. angiogenin), granzyme B, and death associated protein kinase 2 
(DAPK2), all of which have been successfully applied in the context of ITs in vitro and in 
vivo. Although most of the ITs have been tested for toxicity on cancer cells, fully human 
CFPs could be used for other indications as already demonstrated for human granzyme B, 
which specifically kills primary hCD64-positive promyelocytic cells from an acute 
myeloid leukemia (AML) patient ex vivo and to AML-related cell line U937 in vitro after 
delivery by H22(scFv). The cytotoxicity was mediated by the activation of caspase-3, 
leading to the efficient induction of apoptosis at a half-maximal inhibitory concentration 
(IC50) in the range 1.7–17 nM [115]. Interestingly, granzyme B and angiogenin genetically 
fused to H22(scFv) have recently failed to induce apoptosis in primary hCD64tg murine 
macrophages and a hCD64-transfected murine macrophage cell line. These findings 
indicate species-dependent functionality of human enzymes, which apparently require the 
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presence of substrates that are also species-dependent [116]. One aim of this thesis was to 
identify a new cytotoxic effector protein of human origin, which should also be suitable for 
in vivo applications in a transgenic mouse model of chronic cutaneous inflammation. 
 
I.9 Selection of tau as a new cytotoxic effector protein 
A new cytotoxic effector protein suitable for genetic fusion with specific binding 
components was sought by considering proteins critically involved in mitosis. Such 
proteins should conform to the following requirements: 
(1) Induction of apoptosis in target cells   
(2) Fully human sequence 
(3) Small/moderate molecular weight for efficient production in heterologous systems 
(4) No/low off-target toxicity (e.g. by non-specific surface binding) 
(5) Suitability for use in animal models. 
 
The human microtubule-associated protein tau (Gene ID: 4137; from here on referred to 
as MAP) was therefore selected as a candidate. This protein exists in eight isoforms, all 
derived from a single precursor RNA by alternative splicing. Isoform 3 was selected as the 
smallest tau protein still retaining all four microtubule-binding repeats. Microtubule-
associated proteins (e.g. survivin, stathmin, dynactin-1 and MCAK) are involved in the 
regulation of microtubule growth and shortening [117-121], which has been hypothesized 
to critical for the fate of cells in mitosis [122]. In physiologically-healthy cells, they 
orchestrate the fine-tuning of microtubule dynamics, thus allowing these polymers to fulfill 
diverse functions. In resting cells (interphase), microtubules are replaced slowly, with half-
lives of minutes to hours, whereas the microtubule disassembly and polymerization from 
spindle microtubules occurs up to 100 fold more rapidly during mitosis, because this 
increased rate is crucial for successful cell division [123, 124]. The dynamics of 
microtubule assembly and disassembly are under tight spatiotemporal control by 
microtubule-associated proteins, which are themselves regulated by phosphorylation [125]. 
In the context of MAP, the presence of non-phosphorylated molecules during mitosis was 
predicted to reduce the dynamics to a critical degree thus inducing apoptosis, and this 
would be achieved by the removal of critical phosphorylation sites. 
To investigate the potential of MAP to act as a pro-apoptotic effector protein, 
H22(scFv)-MAP and several other MAP-based fusion proteins were generated during this 
project including those used for cancer therapy (EGF-MAP, anti-EpCAM(scFv)-MAP, 
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scFv35-MAP and Ki4(scFv)-MAP). H22(scFv)-MAP was used to target macrophages, and 
only this molecule will be discussed herein. 
 
I.10 Aims and objectives 
During the last decade, macrophages have emerged as promising target cells in many 
different diseases. In particular, these cells play a crucial role in chronic inflammatory 
disorders, which are age-related and widespread. Although macrophages were the first 
immune cells to be described, scientists have only recently gained deeper insight into the 
immunology of this cell type. The identification of different polarized macrophage 
subpopulations, each fulfilling a certain role, has provided opportunities for the 
development of novel treatment strategies focusing on distinct subpopulations rather than 
the total depletion of macrophages. Furthermore, recent advances in targeted 
immunotherapy using ITs, which have advanced from full-length antibodies chemically 
coupled to bacterial toxins, into single chain variants of antibodies genetically fused with 
human enzymes, have broadened the range of possible indications from life-threatening 
diseases such as cancer to also chronic inflammatory diseases. 
The aim of this doctoral thesis was the development of a new M1-targeted therapeutic 
approach for diseases with a chronic inflammatory phase. Therefore, different polarized 
murine macrophages should be profiled extensively at the molecular level, including the 
induction of peritoneal macrophages in hCD64tg mice that will be bred and screened for 
presence of the transgene. Peritoneal macrophages should be isolated and cultured in vitro, 
polarized to M1 and M2a macrophages and characterized for the expression of different 
surface receptors and soluble cytokines, thus providing valuable data to distinguish these 
contrasting subpopulations. Polarized macrophages will be then analyzed using cell 
viability and apoptosis assays with H22(scFv)-ETA' to show whether targeting CD64 – 
one of the surface receptors overexpressed on M1 macrophages – can be used for the 
selective elimination of M1 macrophages while leaving M2a macrophages unaffected. The 
findings will finally be confirmed in a sodium lauryl sulfate (SLS)-induced cutaneous 
inflammation model in hCD64tg mice.  
The results achieved with murine macrophages should be then transferred to humans 
using macrophages derived from peripheral blood mononuclear cells (PBMC) isolated 
from the buffy coats of healthy donors, and polarized to M1 and M2a macrophages in 
vitro. Molecular profiling and functional assays will be repeated in the human system, and 
the clinical relevance will be tested using a human skin biopsy from a patient with atopic 
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dermatitis. This will be treated with H22(scFv)-ETA' ex vivo and analyzed for evidence of 
M1-specific elimination by immunohistochemistry. 
Because classical ITs such as H22(scFv)-ETA' are immunogenic and associated with 
severe side effects, the last part of this work will focus on the identification, generation and 
characterization of a novel fully human CFP. The human MAP will be cloned in frame 
with H22(scFv), expressed in Escherichia coli (E. coli), purified and characterized in vitro 
(binding to target cells, cytoxicity and exploration of the functional mechanism) and in 
vivo, using the transgenic mouse model as described above. 
 
Figure 5. Schematic illustration of the workflow. 
Abbreviations: hCD64tg, human CD64-transgenic; MΦ, macrophage; XTT, cell viability assay; PI, 
propidium iodide; MAP, microtubule-associated protein tau; SDS-PAGE, sodium dodecylsulfate 
polyacrylamide gel electrophoresis; WB, western blotting; IHC, immunohistochemistry. 
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II Materials and Methods 
 
II.1 Materials 
II.1.1 Chemicals and consumables 
Unless otherwise noted, all chemicals and consumables were purchased from the following 
manufacturers: eBioscience; Peprotech; Invitrogen; New England BioLabs; Sigma; Pierce; 
Applied Biosystems; Thermo Fisher Scientific; MWG-Biotech; Roche; Difco; Qiagen; GE 
Healthcare; Stratagene; Fermentas; Promega; Roth; Merk; Dickinson Bioscience; BioRad; 
Biozym; Corning Inc.; Hewlett Packard; Kodak; Eppendorf; Millipore; Novagen; Sarstedt; 
B. Braun; Schott-Glaswerke GmbH; Serva; Whatman; VWR; Labomedic; Falcon; 
Nalgene; NuncTM; Sartorius; Life Technologies; Jackson ImmunoResearch; Kisker 
Biotech; Menzel; Southern Biotech; Greiner; Origene; AppliChem; and Cytoskeleton. 
 
II.1.2 Buffers, media and solutions 
Buffers and stock solutions were prepared according to standard procedures using 
deionized water (dH2O). Ready-to-use RPMI1640 medium was bought from Invitrogen. 
Antibiotics (Sigma) were prepared as stock solutions, filter-sterilized (0.2 μm) and added 
to media after cooling below 50°C. The composition of all common buffers is summarized 
below. 
 
Table 1. Buffers and media. 
  
Buffer  Composition  Concentration  
10x PBS (pH 7.4)  NaCl  
KCl  
Na2HPO4 x 12H2O  
KH2PO4  
1.37  
27  
81  
15  
M  
mM  
mM  
mM  
1x PBST (pH 7.4)  1x PBS    
 Tween 20 0.05  % (v/v)  
TGS (pH 8.3)  Tris-HCl (pH 8.3)  
Glycine  
SDS  
25  
192  
0.1  
mM  
mM  
% (w/v)  
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Buffer Composition Concentration  
TAE (pH 8.2)  Tris  
Glacial acetic acid  
EDTA  
40  
5.7  
10  
mM  
% (v/v)  
mM  
Coomassie Staining 
Solution  
Coomassie Brilliant Blue G-250  
Methanol  
Glacial acetic acid  
0.25  
50  
9  
%(w/v)  
% (v/v)  
% (v/v)  
Coomassie Destaining 
Solution  
Methanol  
Glacial acetic acid  
10  
10  
% (v/v)  
% (v/v)  
5x Protein Loading Buffer  
(reducing) 
Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenol blue  
-Mercaptoethanol  
62.5  
30  
4  
0.05  
10  
mM  
% (v/v)  
% (w/v)  
% (w/v)  
% (v/v)  
SDS PAGE Gel  
(separating gel)  
Acrylamide/Bisacrylamide (30/1)  
Tris-HCl (pH 8.8)  
SDS (10 %, w/v)  
TEMED  
APS  
12  
375  
0.1  
0.1  
0.1  
% (w/v) 
mM  
% (w/v)  
% (v/v)  
% (w/v)  
SDS PAGE Gel  
(stacking gel)  
Acrylamide/Bisacrylamide (30/1)  
Tris-HCl (pH 6.8)  
SDS  
TEMED  
APS  
5  
150  
0.1  
0.1  
0.1  
% (w/v)  
mM  
% (m/v)  
% (v/v)  
% (w/v)  
Binding Buffer (Ni-NTA 
purification, pH 7.5)  
Na2HPO4  
NaCl  
Imidazole  
200  
1000  
5  
mM  
mM 
mM  
Wash Buffer (Ni-NTA 
purification, pH 7.5)  
Na2HPO4  
NaCl  
Imidazole  
50  
1000  
25  
mM  
mM  
mM  
Elution Buffer (Ni-NTA 
purification, pH 7.5)  
Na2HPO4  
NaCl  
Imidazole  
50  
1000 
500  
mM  
mM  
mM  
Blotting Buffer Tris-HCl, pH 8.3 
Glycine 
Methanol 
25 
192 
20 
mM 
mM 
% (v/v) 
AP Buffer Tris-HCl, pH 9.6 
NaCl 
MgCl2 
100 
100 
5 
mM 
mM 
mM 
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II.1.3 Chromatography resins and membranes 
An XK16-20 column filled with IMAC Sepharose 6 Fast Flow resin (both GE Healthcare) 
was used for the enrichment of histidine (His)-tagged proteins via immobilized metal ion 
affinity chromatography (IMAC). Preparative size exclusion chromatography (SEC) was 
carried out using an XK16-70 column packed with SuperdexTM 75 resin. Vivaspin 
Ultrafiltration Devices 30K (Sartorius) were used to concentrate the purified proteins.  
 
II.1.4 Enzymes and reaction kits 
Restriction enzymes, T4 DNA ligase and Phusion High-Fidelity DNA Polymerase were 
purchased from New England BioLabs and used according to manufacturer’s instructions. 
The following kits were used: 
 
Table 2. Names and suppliers of kits. 
Name Supplier 
NucleoSpin Plasmid Macherey-Nagel 
NucleoSpin Extract II Macherey-Nagel 
Gentra Puregene Mouse Tail Kit Qiagen 
 
II.1.5 Antibodies 
Antibodies were used for detection of recombinant proteins on western blots, for analyzing 
the expression level of surface receptors on mammalian cells by flow cytometry, and for 
staining selected surface receptors using IHC and immunofluorescence assays. The 
antibodies used for this thesis are listed below. 
 
Media Composition Concentration  
LB (pH 7.0)  NaCl  
Peptone  
Yeast extract  
1.0 
1.0 
0.5  
% (w/v)  
% (w/v)  
% (w/v)  
SOC  Peptone  
Yeast extract  
NaCl  
KCl  
MgCl2  
MgSO4  
Glucose  
2.0  
0.5 
10  
25  
10  
10  
20  
% (w/v)  
% (w/v)  
mM  
mM  
mM  
mM  
mM 
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Table 3. Antibodies used in this thesis. 
Name Supplier Applications 
Penta-His AlexaFluor488 Qiagen WB 
Mouse-anti-Penta-His Qiagen WB 
Anti-Tau Monoclonal Antibody (HT7)  Thermo Scientific WB 
Goat-anti-Mouse-AP Sigma WB 
Mouse-anti-Human CD64 [10.1]:FITC AbD Serotec  FC, IHC, IF 
Mouse-anti-Human CD64 [10.1]:RPE AbD Serotec  IF 
Rat-anti-Mouse CD301:AlexaFluor488 AbD Serotec  FC, IHC 
Rat-anti-Mouse CD206:FITC AbD Serotec  FC, IHC 
Hamster-anti-Mouse CD11c:RPE AbD Serotec  FC 
Rat-anti-Mouse CD204:FITC AbD Serotec  FC 
Mouse-anti-Mouse CD284:PE eBioscience FC 
Mouse-anti-Human CD284:PE eBioscience FC 
Rat-anti-Mouse CD273:PE eBioscience FC 
Mouse-anti-Human CD273:PE eBioscience FC 
Rat-anti-Mouse CD14:FITC eBioscience FC, IHC 
Mouse-anti-Human CD14:FITC eBioscience FC, IHC 
Rat-anti-Mouse CD205:AlexaFluor488 eBioscience FC 
Mouse-anti-Human CD200R-PE eBioscience FC 
Mouse-anti-Mouse MHCI:FITC eBioscience FC 
Rat-anti-Mouse MHCII:FITC eBioscience FC 
Mouse-anti-Human CD206:PE eBioscience FC, IHC 
Rat-anti-Mouse CD25:AlexaFluor488 eBioscience FC 
Rat-anti-Mouse CD36:PE eBioscience FC 
Rat-anti-Mouse CD39:PE eBioscience FC 
Rat IgG2a K Isotype Control:FITC eBioscience FC 
Rat IgG2a K Isotype Control:PE eBioscience FC 
Mouse-anti-Rat IgG:FITC eBioscience FC 
Rat-anti-Mouse Ki67-FITC eBioscience IF 
Mouse-anti-Human CLEC10A/CD301:AlexaFluor488 R&D Systems FC, IHC 
MOMA-1 Provided by Dr. Georg Kraal1 FC 
MOMA-2 Provided by Dr. Georg Kraal1 FC 
Anti-Mouse-ERTR-9 Provided by Dr. Georg Kraal1 FC 
Abbreviations: WB, western blotting; FC, flow cytometry; IHC, immunohistochemistry; IF, 
immunofluorescence microscopy; 1: Department of Molecular Cell Biology and Immunology, VU University 
Medical Center, Amsterdam, The Netherlands. 
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II.1.6 Synthetic oligonucleotides 
Synthetic oligonucleotides were synthesized by MWG-Biotech and used for DNA 
amplification by polymerase chain reaction (PCR). The sequences of all oligonucleotides 
used for this thesis are listed below. 
 
Table 4. Sequences of oligonucleotides used for PCR. 
# Name Sequence 
1 5_E_NotI_tau3 ATATATATATGAATTCGCGGCCGCAATGGCTGAACCCCGCCAGGAG 
2 3_H_BlpI_tau3 ATATATATATAAGCTTGCTCAGCTCACAAACCCTGCTTGGCCAGGGAG 
3 T610Gf_S204A CAAGTCCAAGATCGGCGCCACTGAG 
4 T610Gr_S204A GTGCTTCAGGTTCTCAGTGGCGCCG 
5 T466Gf_S156A GCACCCCGGCCCTTC 
6 T466Gr_S156A GGGTTGGAAGGGCCGG 
7 H22seqf GTACCGACTTCACCTTCACC 
8 tau3seqf GAAGGGCCAGGCCAAC 
9 H22seqr CGCGTCCCATTCGCC 
10 T7_promoter_f AATACGACTCACTATAG  
11 T7_terminator_r GCTAGTTATTGCTCAGCGG  
12 hCD64f3 TTAAGCATTTCCCTAATGACTATGA 
13 hCD64r1 ACTACCCTCCAAAAAACATCTAAG 
14 mB-actin_f ATATCGCTGCGCTGGTCGTC 
15 mB-actin_r AGGATGGCGTGAGGGAGAGC 
 
II.1.7 Vectors 
The expression vector pMT was used for periplasmic stress expression of recombinant 
H22(scFv)-MAP in E. coli. The pMT vector is derived from the bacterial expression vector 
pET27b (Novagen). It contains the signal peptide pelB, which directs the entire fusion 
protein to the periplasm. Finally, expressed proteins can be isolated from the periplasm and 
enriched by IMAC using an N-terminal His10-tag. 
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Figure 6. Vector map of pMT-H22(scFv)-MAP. 
The vector contains the anti-CD64 single chain fragment H22(scFv) at the N-terminus and MAP at the 
C-terminus. F1 ori, origin of replication for M13 phage; nptI, kanamycin resistance gene; pBR322 origin 
for E. coli, lacI, repressor; T7 promoter, IPTG-inducible promoter; lac operator, controls transcription; 
pelB leader peptide, signal peptide for periplasmic secretion; His-10, poly-histidine sequence used for 
purification and detection of the recombinant protein; EK site; enterokinase cleavage site; 
S156A/S204A, mutations introduced to remove putative phosphorylation sites; repeat 1-4, microtubule-
binding repeats 1-4; NLS, nuclear localization sequence derived from the Simian vacuolating virus 40 
large T antigen; T7 terminator, terminates transcription of the open reading frame. 
 
 
II.1.8 Biological material 
II.1.8.1 Bacterial strains 
E. coli DH5α was used for all intermediate cloning steps and for the amplification of 
plasmid DNA. E. coli BL21(DE3) was used for the expression of recombinant proteins. 
 
Table 5. Names and genotypes of bacterial strains. 
Strain Genotype 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1  
BL21(DE3) F– dcm ompT hsdS(rB– mB–) gal λ(DE3) 
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II.1.8.2 Mammalian cells – cell lines 
The following mammalian cell lines were used for the functional analysis of recombinant 
proteins: 
 
Table 6. Cell lines used in this thesis. 
Cell line  Characteristics  Reference  
HL-60 Human promyelocytic cell line, basal 
CD64 expression, increased expression 
after stimulation with e.g. IFN-γ 
ATCC Nr. CCL-240  
U937  Human cell line derived from histiocytic 
lymphoma, basal CD64 expression, 
increased expression after stimulation 
with e.g. IFN-γ  
ATCC Nr. CRL-1593.2  
L540cy  Human Hodgkin lymphoma derived cell 
line, strong CD30 expression 
DSMZ Nr. ACC 72  
Abbreviations: IFN-γ, interferon γ; ATCC, American Type Culture Collection; DSMZ, Deutsche Sammlung 
von Mikroorganismen und Zellkulturen. 
 
II.1.8.3 Mammalian cells – primary macrophages 
Primary peritoneal mouse macrophages and PBMC-derived human macrophages were 
used for the characterization of polarized macrophages and for the functional analysis of 
recombinant proteins. 
 
II.1.9 Equipment and software 
Balances: Precision and analysis balances, Talent: TE6101, TE64, TE31025, TE12000 
(Satorius) 
Cell Counter: Casy1 (Schaerfe System)  
Cell Washer: Dade Serocent (Baxter)  
Centrifuges: Table centrifuge 5415D and 5415R (Eppendorf), Multifuge 3 S-R / 1S 
(Heraeus Instruments), Avanti J-25I Centrifuge (Beckman Coulter), Rotina 420 R (Hettich 
Zentrifuge)  
Chromatography Equipment: Äkta Purifier (GE Healthcare)  
Cryostat: Cryostat CM 3050 (Leica)  
Rocker/Shaker: Eppendorf Thermomixer comfort, Eppendorf Thermostat 5320 
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Electrophoresis and Blotting: Mini Protean III Gel Chamber, Protein Gel-Apparatus and 
Supplies Mini PROTEAN II™, Gel Air Dryer, Mini Trans-Blot Cell, Mini Trans-Blot Cell 
(all BioRad)  
Flow Cytometer: FACSCalibur (Becton Dickinson) 
Hoods: Hera Safe HS12 (Kendro)  
Incubators: Thermomixer compact (Eppendorf AG), Incubator Function Line Type UT12 
(Heraeus Instruments), CD210 (Binder) 
Microscopes: TCS SP5 Confocal Laser Microscope (Leica), DMIL Inverted Microscope 
with Mercury Fluorescence Light Source (Leica), DM2000 (Leica)  
PCR Thermocyclers: Primus 96 Plus (MWG-Biotech), Programmable Thermal Controller 
PTC-200™ (MJ Research Inc.)  
Sequencer: ABI Prism 3730 Capillary-Sequencer (Applied Biosystems) 
Software: Graph Pad Prism v5.0, Unicorn v5.2, AIDA Image Analyzer, CLC Main 
Workbench v6, Lasergene, Microsoft Excel 2007; Adobe Photoshop CS5.1 Extended; 
WinMDI v2.8 
Sonication: Sonication Probe UW2070 (Bandelin Electronic) 
Spectrophotometer: Epoch Microplate Spectrophotometer (Biotek), Tecan Genios Pro 
Transilluminator: Molecular Imager Gel Doc XR System (BioRad)  
Vortex: Vortex-Genie 2 (Scientific Industries Inc.)  
Water Baths: TE31025, TE12000 (Sartorius) 
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II.2 Methods 
II.2.1 Recombinant DNA technology 
II.2.1.1 Growth and maintenance of E. coli 
Individual colonies were obtained by plating DH5α or BL21(DE3) cells on LB agar plates 
with the appropriate antibiotics and incubating at 37°C. Plates were stored at 4°C for short 
periods (1-2 weeks). LB medium containing the suitable antibiotic (50 μg/ml) was 
inoculated with a single recombinant colony of E. coli and grown overnight at 37°C with 
vigorous shaking (225 rpm). Glycerol stocks were prepared by mixing 600 µl of an 
overnight culture with 400 µl of 50 % (v/v) sterile glycerol and storing at –80°C. 
 
II.2.1.2 Transformation of E. coli by heat shock 
Chemically competent E. coli cells (100 µl aliquots) were thawed on ice and mixed gently 
with 50–100 ng of DNA. The cell/DNA mixture was incubated for 30 min on ice and then 
heat shocked at 42°C for 30 s. The bacteria were then transferred back on ice for 2 min, 
400 µl of LB medium was added and the cells were incubated at 37°C with shaking for 30–
60 min. Finally, 300 µl of the cells were plated onto LB agar supplemented with 
appropriate antibiotics and incubated at 37°C overnight. 
 
II.2.1.3 Periplasmic protein expression under osmotic stress  
Recombinant proteins were expressed in E. coli BL21(DE3) cells using the protocol for 
periplasmic stress expression in the presence of compatible solutes as previously described 
[126]. Briefly, after transformation bacteria were grown to an OD of 1.6 followed by stress 
induction with 500 mM D-sorbitol, 10 mM betaine monohydrate and 4% (w/w) NaCl. 
After incubation at 26°C for 30 min with shaking (180 rpm), protein expression was 
induced with 2 mM IPTG. Bacteria were harvested 18 h after induction by centrifugation 
(4000 x g, 10 min, 4°C) and frozen at –80°C overnight. The frozen pellet was resuspended 
in preparation buffer (75 mM Tris-HCl, 300 mM NaCl, 5 mM DTT, 10 mM EDTA, 10% 
(v/v) glycerol, pH 8.0) containing a complete protease inhibitor cocktail (Roche) at 4°C 
and sonicated five times for 60 s at 200 W. Cell debris was removed by centrifugation 
(24,000 x g, 20 min, 4°C) and EDTA was removed by dialysis against phosphate-buffered 
saline (PBS) plus 1 M NaCl (pH 7.4) at 4°C overnight. The cleared bacterial lysate was 
then used for protein purification by IMAC. 
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II.2.1.4 Cell culture – mammalian cell lines 
Mammalian cell lines were cultivated in complete medium (RPMI1640) supplemented 
with 10% (v/v) fetal calf serum (FCS), 50 µg/ml penicillin and 100 µg/ml streptomycin (all 
Invitrogen). Cell cultures were incubated at 37°C, 100% humidity and 5% CO2, and were 
split twice a week. The cell number was monitored using the cell counter Casy1 (Schaerfe 
System). Before analyzing CD64 expression, HL-60 and U937 were stimulated with 
50 units (U)/ml IFN-γ for 24 h. 
 
II.2.1.5 Isolation and culture of primary macrophages 
Peritoneal macrophages were induced by the intraperitoneal injection of 1 ml 2% (w/v) 
BioGel P-100 (BioRad) into hCD64tg mice. After 3 days, the mice were sacrificed and 
macrophages were isolated by peritoneal lavage using 5 ml cold PBS (pH 7.4). After the 
lysis of red blood cells, macrophages were cultured at a concentration of 0.5–1.0 x 106 
cells/ml in complete medium in T75 tissue culture flasks for 2–4 h. Non-adherent cells 
were removed by washing with cold PBS (pH 7.4) and macrophages were detached by 
incubation with cold 0.5 mM EDTA in PBS (pH 7.4) for 10 min on ice. An appropriate 
number of cells was then seeded into assay plates and incubated overnight, before 
polarization to either M1 macrophages using 100 U/ml IFN-γ (Peprotech) and 1 µg/ml LPS 
(Sigma) or M2 macrophages using 20 ng/ml IL-4 (Peprotech) for 24 h. Non-polarized 
macrophages (M0) were used as a control. 
Human monocytes were isolated from buffy coats by density gradient centrifugation 
with Ficoll (VWR) and cultured overnight as described above. Non-adherent cells (e.g. B 
and T cells) were removed by washing. After the appropriate stimulus, cells were 
incubated for 72 h. Finally, stimuli were boosted with 50% of the initial concentration for 
24 h and the macrophages were used in functional assays.   
 
II.2.1.6 Isolation of plasmid DNA from E. coli 
Plasmid DNA was purified using the NucleoSpin Plasmid Kit (Macherey-Nagel) according 
to the manufacturer’s instructions and stored at –20°C. 
 
II.2.1.7 Analytical agarose gel electrophoresis 
Plasmid DNA, restriction fragments and PCR products were separated by 0.8–1.2% (w/v) 
agarose gel electrophoresis using gels prepared in TAE buffer containing 0.5 μg/ml 
ethidium bromide. Samples were loaded with OrangeG Loading Buffer (New England 
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BioLabs). DNA markers such as the 2-Log DNA ladder (New England BioLabs) were 
used to evaluate sample size and integrity. The DNA was visualized at 302 nm and 
documented using a Molecular Imager Gel Doc XR System (BioRad). 
 
II.2.1.8 Preparative agarose gel electrophoresis 
Preparative gel electrophoresis was used to isolate particular DNA fragments from a 
mixture after restriction enzyme digestion. Agarose blocks containing the DNA fragment 
of interest were excised from the gel on an UV transilluminator with a sterile blade. DNA 
was extracted using a NuceloSpin Extract II kit (Macherey-Nagel) according to the 
manufacturer’s guidelines and stored at –20°C. 
 
II.2.1.9 Quantification of DNA 
DNA concentrations were determined by measuring the OD260nm (1.0 corresponds to 
~50 μg/ml of double stranded DNA). The purity of the nucleic acid was determined by 
measuring the OD260/280nm ratio, which is 1.8 or higher for pure DNA.  
 
II.2.1.10 PCR amplification 
PCR was used for DNA amplification, to add appropriate restriction sites to the 5' and 3' 
ends, and to remove putative phosphorylation sites from the MAP sequence by site-
directed mutagenesis. Typical PCR preparations contained following components: 
 
Table 7. PCR pipetting scheme. 
Component Volume Final concentration 
Forward Primer 1 μl 10 pM 
Reverse Primer 1 μl 10 pM 
10 mM dNTP-Mix 1 μl 500 µM each 
5x Phusion HF Buffer 4 μl 1x 
Phusion DNA Polymerase 0.2 μl 0.02 U/µl 
Template DNA 5 μl 1 ng/μl 
dH2O 7.8 μl - 
Total 20 μl  
 
     The optimal melting temperature Tm was estimated using the Tm Calculator from New 
England BioLabs. All reactions were carried out in 0.5 ml PCR tubes using a PCR 
thermocycler under the cycling conditions stated below: 
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Table 8. PCR cycling conditions. 
Cycle Step Temperature Time  
Initial Denaturation 98°C 30 s  
Denaturation 98°C 10 s  
Annealing  x°C 30 s x 25-35 
Extension 72°C 30 s/kb  
Final Extension 72°C 5 min  
Pause 4°C Hold  
 
PCR products were resolved on 0.8-1.2 % (w/v) agarose gels (II.2.1.8) using the 2-Log 
DNA Ladder as a marker to confirm successful amplification and product integrity. 
 
II.2.1.11 Restriction of DNA 
Restriction endonucleases, 10x buffers 1, 2, 3 and 4, and bovine serum albumin (BSA) 
solution were obtained from New England BioLabs. DNA was incubated with the 
corresponding enzyme and buffer in a heating block at 37°C for 20 min for analytical and 
1–2 h for preparative digestion. Digestion with SfiI was carried out at 50°C for 2 h. 
 
II.2.1.12 Ligation of DNA 
DNA fragments were ligated using T4 DNA Ligase (400,000 U/ml; New England 
BioLabs) using 10x ligase buffer as recommended in the manufacturer’s protocol in a final 
volume of 20 μl. Six-fold molar excess of insert DNA to vector DNA was used to ensure 
successful ligation. Ligation was carried out for 60 min at room temperature or at 15°C 
overnight followed by the transformation of E. coli. 
 
II.2.1.13 DNA sequencing and analysis 
Sequence analysis was carried out at the Fraunhofer IME sequencing facility using an ABI 
Prism 3700 Capillary-Sequencer (Applied Biosystems) with BigDye™ cycle sequencing 
terminator chemistry and the Applied Biosystems Sequencing Analysis Program. The 
sequences were analyzed with Lasergene software. 
 
II.2.2 Protein purification 
II.2.2.1 Immobilized metal ion affinity chromatography (IMAC) 
Recombinant H22(scFv)-MAP was enriched by IMAC on an Äkta Purifier System (GE 
Healthcare) using IMAC Sepharose 6 Fast Flow as resin (GE Healthcare). Bacterial lysate 
was cleared by vacuum filtration using a 1-µm Whatman filter before loading onto an 
XK16-20 column at a flow rate of 1–2 ml/min. After loading, the column was washed with 
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Wash Buffer (25 mM imidazole) until the baseline was reached. Elution was carried out at 
a flow rate of 1 ml/min using Elution Buffer (500 mM imidazole). Finally, the eluted 
protein fraction was concentrated using a Vivaspin Ultrafiltration Device 30K (Sartorius) 
in preparation for SEC.  
 
II.2.2.2 Preparative size exclusion chromatography (SEC) 
Preparative SEC was carried out on an Äkta Purifier System (GE Healthcare) using an 
XK16-70 column packed with SuperdexTM 75 (GE Healthcare), using PBS (pH 7.4) as the 
mobile phase at a flow rate of 1.0 ml/min. Protein elution was monitored at A280nm. 
Collected fractions were analyzed by sodium dodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) for protein size and purity. Selected fractions were then 
combined, concentrated, filter-sterilized (0.2 μm), aliquoted and stored at –20°C. 
 
II.2.3 Protein analysis 
II.2.3.1 Quantification of purified proteins 
Purified proteins were quantified using the Roti-Nanoquant (Roth) Bradford Assay 
according to the manufacturer’s instructions. Serially diluted BSA (Sigma) at known 
concentrations was used to generate a standard curve. The final determination of protein 
concentration was performed with Microsoft Excel 2007. 
 
II.2.3.2 Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)   
Discontinuous SDS-PAGE was used for the separation of protein samples. Before loading 
onto the gel, protein samples were diluted in PBS (pH 7.4) and 5x Protein Loading Buffer 
and heated at 95°C for 5 min. Proteins were separated electrophoretically at 180 V for 60 
min. Protein bands were visualized by staining with Coomassie Staining Solution for 20 
min at room temperature. Non-specific background staining was removed by washing with 
Coomassie Destaining Solution until the protein bands were clearly visible. 
 
II.2.3.3 Western blotting 
Western blotting was used to detect separated proteins using specific antibodies. Proteins 
were transferred from the gel to a nitrocellulose membrane using the electro-tank blotting 
method (300 mA; 60 min) followed by blocking with 1x Roti-Block (Roth) for 1 h at room 
temperature or 4°C overnight. After blocking, the membrane was washed three times with 
1x PBST. H22(scFv)-MAP was detected using anti-Tau Monoclonal Antibody (1:25,000; 
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Thermo Scientific) for 45–60 min at room temperature. The membrane was washed as 
described above and the primary antibody was detected using an alkaline phosphatase-
conjugated anti-mouse-IgG mAb (1:5,000; Sigma) followed by extensive washing with 1x 
PBST. Prior to final staining with NBT/BCIP substrate (Life Technologies), the membrane 
was equilibrated in 1x AP buffer for 5 min at room temperature. Pre-stained broad range 
protein markers (New England BioLabs) were used as a reference. 
  
II.2.4 Immunoassays 
II.2.4.1 Flow cytometry 
II.2.4.1.1 Binding analysis 
The cell-binding activity of purified proteins was analyzed by flow cytometry by first 
incubating 4 x 105 cells with 1 µM recombinant protein in PBS (pH 7.4) containing 2 mM 
EDTA and 0.5% (w/v) BSA (Sigma) for 30 min on ice followed by washing with PBS 
(pH 7.4). Fluorescence staining with anti-Penta-His AlexaFluor488 antibody (1:100; 
Qiagen) for 30 min on ice in the dark was followed by washing twice with PBS (pH 7.4) 
and subsequent analysis using a FACSCalibur flow cytometer (Becton Dickinson). 
  
II.2.4.1.2 Profiling of polarized macrophages 
The expression of surface receptors on polarized macrophages was analyzed by flow 
cytometry. Cells were incubated with a fluorophore-labeled antibody in PBS (pH 7.4) 
containing 2 mM EDTA and 0.5% (w/v) BSA (Sigma) for 30 min on ice followed by 
washing twice with PBS (pH 7.4). The fluorescence was then analyzed on a FACSCalibur 
flow cytometer (Becton Dickinson) and the results were presented as relative fluorescence 
intensity calculated as follows:  
Relative surface expression = (MFIantibody – MFIisotype control)/MFIisotype control). 
Comparisons between M1 and M2 polarized macrophages were presented as log(M1/M2) 
or log(M2/M1) values. 
 
II.2.4.2 Measuring soluble cytokines 
The production of soluble cytokines such as IL-12, IL-6, TNF-α, IL-1α and IL-10 was 
measured by FlowCytomix according to the manufacturer’s instructions (eBioscience). The 
concentration of murine RELM-α was determined using a sandwich enzyme-linked 
immunosorbent assay (ELISA) as follows. High-binding 96-well flat-bottom microtiter 
plates (VWR) were coated with 1 µg/ml rabbit-anti-mouse RELM-α antibody (Peprotech) 
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in PBS (pH 7.4) at 4°C overnight followed by blocking with 2% (w/v) BSA (Sigma) in 
PBS (pH 7.4) for 2 h at room temperature. All intermediate washing steps were carried out 
five times for 5 min using 1x PBST. Standard samples and supernatants were applied to the 
plate in a total volume of 100 µl and incubated at 4°C overnight. The captured cytokines 
were detected using 0.5 µg/ml of biotinylated rabbit-anti-mouse RELM-α (Peprotech) for 
1 h at room temperature and bound antibodies were detected using horseradish peroxidase 
(HRP)-conjugated streptavidin (Jackson ImmunoResearch) at a concentration of 1 µg/ml 
for 30 min at room temperature. Finally, the wells were extensively washed with 1x PBST 
and incubated with TMB substrate (eBioscience) until color development. The staining 
reaction was stopped using 1 M H3PO4 and the signal was monitored at OD450-570nm using 
an Epoch Microplate Spectrophotometer (Biotek). Data were analyzed using Graph Pad 
Prism v5 software. All experiments were carried out in triplicate. 
 
II.2.4.3 In vitro plasticity of polarized macrophages 
To study the plasticity of polarized macrophages, cells were re-stimulated with the reverse 
stimulus (IL-4 for M1 and IFN-γ for M2) for 24 h. Before re-polarization, the medium 
containing the initial stimulus was changed and the cells were washed with PBS (pH 7.4). 
The re-polarizing stimuli (20 ng/ml IL-4 for M1 and 100 U/ml IFN-γ) were diluted in fresh 
complete medium and added to the cells before incubating for a further 24 h. The cells 
were then analyzed for the expression of selected surface receptors by flow cytometry 
(II.2.4.1.2). Cytokine profiles were analyzed by FlowCytomix/ELISA (II.2.4.2). 
Polarization for 48 h was used as control. 
 
II.2.4.4 Cell viability assay 
The cytotoxic effect of recombinant proteins was assessed by measuring the conversion of 
XTT to a water soluble orange formazan dye as previously described [127]. Briefly, 
5 x 105 cells/well were seeded into a 96-well microtiter plate and incubated at 37°C, 5% 
CO2 and 100% humidity overnight. After stimulation for 24 h, various dilutions of the 
recombinant protein were added to the wells and the cells were incubated for further 72 h 
as above. For the readout, 50 µl of XTT/phenanzine methosulfate (100:1; Serva and 
Sigma-Aldrich) was added to each well followed by incubation for 3–4 h. The absorbance 
was measured at 450 and 630 nm using an Epoch Microplate Spectrophotometer (Biotek). 
The concentration required to achieve a 50% reduction of protein synthesis (IC50) relative 
Materials and Methods 
32 
 
to untreated control cells was calculated using the GraphPad Prism v5 software. All 
experiments were carried out in triplicate. 
 
II.2.4.5 Apoptosis assay 
To confirm the apoptosis-inducing effect of H22(scFv)-ETA' and H22(scFv)-MAP, an 
AnnexinV/propidium iodide (PI) assay was carried out by incubating 2.5 x 105 cells/ml 
with a defined amount of recombinant protein in a 12-well plate (Greiner) for 24 h at 37°C, 
5% CO2 and 100% humidity. PBS (pH 7.4), zeocin (0.5 mg/ml) and the CD64- cell line 
L540cy were used as controls. After incubation, the cells were washed twice with PBS 
(pH 7.4) and stained with AnnexinV-FITC (eBioscience) in AnnexinV binding buffer (10 
mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2) for 30 min at room 
temperature. Finally, the cells were washed as described above, resuspended in AnnexinV 
buffer containing 10 µg/ml PI and analyzed by flow cytometry using a FACSCalibur 
device (Becton Dickinson). 
 
II.2.4.6 Assessment of endosomal protease activity 
The endosomal protease activity in different polarized macrophages was compared by 
coupling 3-µm amino-modified silica beads (Kisker Biotech) to DQ Ovalbumin 
(Invitrogen), a pH stable protease substrate that is fluorogenic following proteolysis. 
Therefore, 50 mg/ml silica beads (in PBS, pH 7.4) were activated using 10 mg/ml Sulfo-
SMCC (in DMF; Sigma) for 1 h at room temperature with agitation. The beads were 
washed twice with PBS (pH 7.4) followed by incubation with 1 mg/ml DQ Ovalbumin (in 
PBS, pH 7.4) for 2 h at room temperature and at 4°C overnight. Finally, the beads were 
washed twice with PBS (pH 7.4), resuspended and stored at 4°C. For the relative 
quantification of endosomal protease activity, polarized macrophages were incubated with 
0.25 mg/ml of DQ Ovalbumin modified silica beads for 15 min at room temperature and 
for an additional 15 min at 37°C. The cells were washed twice with warm PBS (pH 7.4) 
before 1 ml of fresh complete medium was added. The fluorescence intensity at 520 nm 
was measured every 15 min using a Tecan Genios Pro spectrophotometer. The scope of the 
linear phase was used for comparison of endosomal protease activities. 
 
II.2.4.7 Tubulin polymerization assay 
The stabilizing effect of H22(scFv)-MAP on tubulin polymerization was tested using a 
Tubulin Polymerization Assay Kit (Cytoskeleton) according to manufacturer’s 
Materials and Methods 
33 
 
instructions. Paclitaxel and general tubulin buffer were used as controls. All measurements 
were carried out in duplicate. Vmax represents the slope of the linear phase in milli-
extinction units (mE). 
 
II.2.4.8 Proliferation assay 
The stimulation-dependent proliferation of HL-60 cells was analyzed using PI staining. 
After seeding equal numbers of cells per well, the cells were stimulated with 50 U/ml 
IFN-γ or 20 ng/ml phorbol 12-myristate 13-acetate (PMA) for 24 h, washed once with PBS 
(pH 7.4) and incubated in PBS with 0.05% (v/v) Triton X-100, 0.1 mg/ml RNAse A 
(AppliChem) and 50 µg/ml PI for 40 min at 37°C. Finally, the cells were washed once with 
PBS (pH 7.4) and cell cycle analysis was carried out by flow cytometry (FL-2A channel). 
Proliferation was also determined by cell counting using the Casy1 cell counter (Schaerfe 
System). All experiments were carried out in triplicate. 
 
II.2.4.9 Immunofluorescence microscopy 
To test the ability of M1 macrophages to proliferate in vivo, sections from inflamed mouse 
skin were double-stained with rat-anti-mouse Ki67-FITC (marker for proliferation; 
eBioscience) and mouse-anti-human CD64 [10.1]-RPE (M1 marker; AbD Serotec). Skin 
sections were fixed for 10 min with dry acetone, air-dried and incubated with pre-mixed 
antibodies at 4°C overnight. Slides were washed three times for 5 min with 1x PBST and 
analyzed using a TCS SP5 Confocal Laser Microscope (Leica). Images were processed 
using Photoshop CS5 Extended software. 
  
II.2.4.10 Immunohistochemistry 
Biopsy specimens were cut into 8-µm sections on a Cryostat CM 3050 (Leica) and 
mounted on coated slides (Menzel). After drying for 48–72 h, sections were fixed for 
10 min with dry acetone, air-dried and incubated with the primary antibody at 4°C 
overnight. The primary antibodies were: mouse-anti-human CD64 [10.1]-FITC (AbD 
Serotec, Germany, 1:40), mouse-anti-human CD14-FITC, rat-anti-mouse CD14-FITC 
(both eBioscience, Germany, 1:40), and rat-anti-mouse CD206-FITC (AbD Serotec, 
Germany, 1:40) in 1% (v/v) normal mouse serum (Invitrogen) in PBS (pH 7.4); mouse-
anti-human CD206-PE (eBioscience, Germany, 1:40), rat-anti-mouse CD301-
AlexaFluor488 (AbD Serotec, Germany, 1:40), and mouse-anti-human CD301-
AlexaFluor488 (R&D Systems, Germany, 1:40) in 1% (v/v) normal goat serum (Sigma) in 
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PBS (pH 7.4). Slides were washed three times for 5 min with 1x PBST, then incubated 
with AP-conjugated sheep anti-FITC (Southern Biotech, 1:400) in 1% (v/v) sheep serum 
(Sigma) in  PBS (pH 7.4; 45 min) or AP-conjugated goat-anti-rat antibody (eBioscience, 
1:400) in 1% (v/v) goat serum in PBS (pH 7.4; 45 min). After washing twice in 1x PBST 
and once in Tris-HCl (0.1 M, pH 8.5), AP activity was detected using the substrate 
naphthol AS-BI phosphate (sodium salt, 500 mg/l; Sigma) and new fuchsin (100 mg/l; 
Merck) as the chromogen dissolved in 0.1 M Tris-HCl, pH 8.5, resulting in pink/red 
staining. Endogenous AP activity was inhibited by adding levamisole (350 mg/l, Sigma) to 
the reaction mixture. Slides were lightly counterstained with hematoxylin. 
 
II.2.4.11 Image analysis 
Images of stained tissue sections were acquired using a microscope-assisted camera at 10x 
magnification, and were stitched into a large image using Adobe Photoshop CS5.1 
Extended software. After stitching and blending single sections to one image, the reddish 
color of stained cells was selected and the number of pixels was determined, representing 
the area occupied by stained cells. This area was normalized to the total image area and the 
resulting number represented the relative area occupied by stained cells per unit of total 
image area. 
 
II.2.5 Animal work and human patient material 
II.2.5.1 Ethics statement 
Human skin biopsy material was collected at the Sankt Franziskus Hospital in Aachen 
according to the guidelines of the University Hospital Aachen ethical committee. The 
committee specifically approved this study. Written consent was obtained from the patient. 
 
II.2.5.2 Human patient material 
One skin biopsy specimen from a patient with atopic dermatitis was analyzed. The 
specimen (4 mm in diameter) was taken from an inflamed region. For experiments, the 
specimen was divided into four pieces and incubated in complete medium supplemented 
with 1 µM H22(scFv)-ETA' for 24 or 48 h. Control specimens were incubated for the same 
time in cell culture medium only, in order to capture IT-independent dying or out-
migration of macrophages. One piece of the tissue was immediately frozen in liquid 
nitrogen and stored at –80°C until final analysis by immunohistochemistry (here referred to 
as “untreated”).  
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II.2.5.3 SLS-induced cutaneous inflammation model 
The experiments were officially approved by the local Animal Care and Use Review 
Committee. All animals received humane care in accordance with the requirements of the 
German Tierschutzgesetz, §8 Abs. 1 and the Guide for the Care and Use of Laboratory 
Animals published by the National Institutes of Health in 2011. In all experiments nude 
transgenic male C57/Bl6/SKH1-E mice greater than 6 weeks old and expressing hCD64 
were used. To induce chronic cutaneous inflammation, 5% (w/v) SLS in PBS was applied 
to a 1.5 x 1.5 cm skin surface area on both flanks of each mouse daily for 11 consecutive 
days. Before the administration of H22(scFv)-ETA' or H22(scFv)-MAP, animals were 
anaesthetized with isofluran. Three intradermal injections of 20 µl of 1 µM recombinant 
protein, or PBS (pH 7.4) control, were administered contralaterally. Finally, the animals 
were sacrificed and skin biopsies were taken, snap frozen in liquid nitrogen, and stored at  
–80°C prior to further analysis. 
 
II.2.6 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism v5 software. Data were 
expressed as the mean ± standard deviation (SD) or standard error of mean (SEM), as 
indicated. Statistical comparisons were made using a two-tailed unpaired Student’s t test, 
one-way or two-way ANOVA, where appropriate. *p≤0.05, **p≤0.01, ***p≤0.001. 
 
II.2.7 Safety levels and approval for animal experiments 
All experiments were carried out according to the S1 (file numbers: 64-K-1.19/01 and 521-
K-1.10/99) or S2 (file numbers: 64-K-1.20/01 and 521-K-1.5/95) safety level, as required. 
The animal experiment was officially approved by the Landesamt für Natur, Umwelt und 
Verbraucherschutz (LANUV); file number: 8.87-50.10.35.08.088. 
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III Results 
 
The aim of this thesis was to investigate the immunology of polarized macrophages and to 
find a suitable strategy for targeting the pro-inflammatory M1 subpopulation selectively. 
Initial targeting experiments demonstrating the proof of concept were performed using the 
well characterized IT H22(scFv)-ETA'. In addition to ETA', a novel cytotoxic effector 
protein was identified, characterized in terms of its pro-apoptotic activity in target cells, 
and used to replace the bacterial toxin ETA'. Both fusion proteins were then tested in vivo. 
The results section is therefore subdivided into three parts: 
The first part shows how murine and human polarized macrophages were generated and 
characterized in terms of their surface receptor expression and cytokine profiles. This part 
concludes with functional assays using H22(scFv)-ETA'. The second part deals with the 
identification, generation and in vitro characterization of the new cytotoxic protein MAP 
fused to H22(scFv). The final part demonstrates the in vivo activity of both fusion proteins 
in a cutaneous chronic inflammation model in transgenic mice and in a human skin biopsy 
derived from a patient with atopic dermatitis. 
 
III.1 CD64-mediated targeting of pro-inflammatory M1 macrophages 
III.1.1 Breeding and screening of hCD64tg mice 
H22(scFv) can only be used in a mouse model expressing the corresponding human 
receptor, hence the need for hCD64tg mice. Therefore, hCD64tg mice were bred and 
screened in the Fraunhofer IME animal facility. One heterozygous 
hCD64tg/C57/BL6/SKH1-E male was mated with 3–5 non-transgenic C57/BL6/SKH1-E 
females and the offspring segregated according to Mendel’s law. Before this project, the 
mice were screened by analyzing blood monocytes for the expression of hCD64 using flow 
cytometry. However, this requires animals to be at least 5–6 weeks old, as a sufficient 
volume of blood for flow cytometry cannot be withdrawn from younger mice without 
endangering life. To reduce the waiting period, a new PCR-based method was established 
in which 3-week-old mice were ear-labeled using a tissue puncher, and the 2-mm sample 
was used for the isolation of genomic DNA with the Gentra Puregene Mouse Tail Kit 
(Qiagen) according to the manufacturer’s instructions. Isolated DNA was amplified using 
hCD64 gene-specific primers, yielding a 629-bp product. The optimal annealing 
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temperature and number of cycles were determined empirically, and the pipetting scheme 
and running conditions are summarized in Table 9 and Table 10, respectively. 
 
Table 9. Pipetting scheme for hCD64-specific PCR. 
Component Volume Final concentration 
Forward Primer #12 1 μl 10 pM 
Reverse Primer #13 1 μl 10 pM 
10 mM dNTP-Mix 1 μl 500 µM each 
5x Phusion HF Buffer 4 μl 1x 
Phusion DNA Polymerase 0.2 μl 0.02 U/µl 
Template DNA 5 μl - 
dH2O 7.8 μl - 
Total 20 μl  
 
Table 10. Cycling conditions for hCD64-specific PCR. 
Cycle Step Temperature Time  
Initial Denaturation 98°C 30 s  
Denaturation 98°C 10 s  
Annealing  53°C 30 s x 30 
Extension 72°C 30 s  
Final Extension 72°C 5 min  
Pause 4°C Hold  
 
A mouse β-actin PCR was set up as a control to confirm the quality of the isolated 
genomic DNA. Mouse β-actin gene-specific primers were designed to generate a 1057-bp 
product. The optimal running conditions for the control PCR and results from both 
experiments are summarized below. 
 
Table 11. Pipetting scheme for β-actin-specific PCR. 
Component Volume Final concentration 
Forward Primer #14 1 μl 10 pM 
Reverse Primer #15 1 μl 10 pM 
10 mM dNTP-Mix 1 μl 500 µM each 
5x Phusion HF Buffer 4 μl 1x 
Phusion DNA Polymerase 0.2 μl 0.02 U/µl 
Template DNA 5 μl - 
DMSO 1 µl - 
dH2O 6.8 μl - 
Total 20 μl  
 
Table 12. Cycling conditions for β-actin-specific PCR. 
Cycle Step Temperature Time  
Initial Denaturation 98°C 30 s  
Denaturation 98°C 10 s  
Annealing  60°C 60 s x 50 
Extension 72°C 60 s  
Final Extension 72°C 5 min  
Pause 4°C Hold  
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Figure 7. PCR results for the screening of hCD64tg mice. 
PCR was carried out as described (II.2.1.10). Genomic DNA was amplified with gene-specific primers 
for hCD64 and mouse β-actin, and separated on a 1.2% (w/v) agarose gel (II.2.1.7). M, 2-log-DNA 
ladder (Invitrogen); 1, mouse #1 (hCD64tg); 2, mouse #2 (non-transgenic); 3, human DNA (positive 
control); 4, mouse DNA (negative control). Abbreviations: bp, base pairs. 
 
In summary, the PCR protocol for hCD64tg mice provides multiple advantages over the 
flow cytometry-based screening approach: 
(1) Time saving: 2-3 weeks (3-week-old mice can be screened) 
(2) No blood withdrawal: ear punch for labeling is used for DNA isolation 
(3) No expensive antibodies: standard PCR reagents can be used 
(4) Sensitive and robust detection of the transgene: no false positive results 
 
III.1.2 Profiling of polarized macrophages 
The polarization of macrophages is a plastic, dynamic and flexible process. M1 and M2 
represent two extremes of a continuum, which means that every possible hybrid population 
may exist. Therefore, one of the aims of this thesis was to extensively characterize 
polarized macrophages in terms of their membrane-bound and soluble proteins. 
 
III.1.2.1 Expression of surface receptors 
The expression of surface receptors on polarized macrophages was quantified by flow 
cytometry as described (II.2.4.1.2). The selection of surface receptors for testing was based 
on published data and the results are presented as relative fluorescence intensity calculated 
as follows:  
Relative surface expression = (MFIantibody – MFIisotype control)/MFIisotype control. 
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Figure 8. Screening of M1-specific and M2-specific surface markers. 
Screening of surface markers on (A) hCD64tg mouse macrophages and (B) human PBMC-derived 
macrophages was carried out by flow cytometry (II.2.4.1.2). M1/M2 ratio > 0 = upregulation in M1 
cells; M1/M2 ratio < 0 = upregulation in M2 cells. Data are representative of three independent 
experiments and are presented as means ± SD. 
 
For mouse macrophages, eight receptors were found to be upregulated in M1 
macrophages including the FcγRI (CD64), the co-receptor for LPS (CD14), two scavenger 
receptors (CD36 and CD204), the α-chain of the IL-2 receptor (CD25), the membrane-
bound ATP-hydrolyzing enzyme CD39, and both MHC molecules. In contrast, M2 
macrophages downregulated CD64 and CD14 but the levels of the programmed cell death 
1 ligand 2 (CD273), Toll-like receptor 4 (CD284), and the macrophage galactose-type 
C-type lectin (CD301) were higher than in M1 cells. In contrast to previously published 
data on M2 macrophages generated by addition of GM-CSF and IL-4, the mannose 
receptor (CD206) was specifically upregulated by IL-4 in a GM-CSF-independent manner. 
Integrin CD11c, C-type lectins CD209 and CD205, and sialoadhesins recognized by 
MOMA-1 and MOMA-2 were also found on M2-polarized macrophages (Figure 8-A).  
 Human macrophages were tested for the expression of a preselected set of markers. The 
upregulation of CD64 and CD14 in human M1 macrophages agreed with the murine data. 
FcγRIII (CD16) and CD80 expression were also upregulated, the latter involved in T cell 
regulation by binding to CD28 and CTL-4, and in T cell priming when combined with 
CD86. Two of the murine M2 markers (CD273 and CD284) showed the inverse expression 
profile in human macrophages, and human M2 macrophages also downregulated CD64 
and CD14 but upregulated the hemoglobin scavenger receptor CD163, CD206 and CD301. 
The glycoprotein receptor OX-2 (CD200R) was also strongly overexpressed (Figure 8-B). 
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III.1.2.2 Production of soluble cytokines 
Polarization also induced a change in the expression of soluble cytokines. Whereas both 
murine and human M1 macrophages secreted large amounts of the pro-inflammatory 
cytokine IL-12, only residual IL-12 was secreted by M2 macrophages. The pro-
inflammatory cytokines TNF-α and IL-6 were also strongly upregulated in murine and 
human M1 macrophages, whereas RELM-α expression doubled in murine M2 
macrophages. The anti-inflammatory cytokine IL-10 was detected at comparable levels in 
both macrophage populations (Figure 9). 
 
 
Figure 9. Expression of soluble cytokines by polarized macrophages. 
The supernatants of polarized macrophages were analyzed for soluble cytokines as described (II.2.4.2). 
Data represent three independent experiments and are presented as means ± SD. Statistical analysis was 
carried out using a two-tailed unpaired Student’s t test. *p≤0.05, **p≤0.01, ***p≤0.001. Abbreviations: 
b.d., below detection limit. 
 
 
 
III.1.2.3 Functional assays with polarized macrophages 
III.1.2.3.1 Binding of H22(scFv) to polarized macrophages 
The binding of H22(scFv) to polarized macrophages was analyzed by flow cytometry 
(II.2.4.1.1) in preparation for targeting experiments with H22(scFv)-based ITs. H22(scFv) 
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was shown to bind all polarized subpopulations as shown in Figure 10. Compared to M0 
and M2 macrophages, the expression of hCD64 was upregulated in M1 macrophages.  
 
 
Figure 10. Expression of hCD64 on the surface of polarized macrophages. 
Representative results showing the expression of hCD64 on the surface of transgenic murine 
macrophages (II.2.1.5), as determined by flow cytometry (II.2.4.1.2). 
 
 
III.1.2.3.2 M1-selective cytotoxicity of H22(scFv)-based ITs 
The upregulated expression of hCD64 should allow the targeting of M1 macrophages using 
H22(scFv)-based ITs. Cell viability assays were therefore carried out as described 
(II.2.4.4), including M0 and M2 macrophages to test the specificity of these constructs. 
Both murine and human macrophages were tested, but murine macrophages could only be 
tested in combination with the bacterial ETA' toxin because of the species-dependent 
activity of the fully human CFPs H22(scFv)-Ang and Gb-H22(scFv). As result, 
H22(scFv)-ETA' could selectively eliminate both murine and human M1 macrophages 
with IC50 values of 25 and 214 pM, respectively. Similar results were obtained in human 
macrophages for H22(scFv)-Ang (IC50 = 108 pM) and Gb-H22(scFv) (IC50 = 139 pM). M0 
and M2 macrophages were unaffected by either IT (Figure 11). Because M0 macrophages 
showed minimal metabolic activity, the cell viability assays are less reliable for this 
subpopulation. More accurate results for M0 macrophages were achieved using apoptosis 
assays as shown below (Figure 12). H22(scFv) alone did not affect the viability of either 
macrophage population. These results confirm the selective activity of H22(scFv)-
delivered toxic molecules against M1 macrophages.  
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Figure 11. H22(scFv)-based ITs are selectively toxic towards M1 macrophages. 
Cell viability assays were carried out as described (II.2.4.4). H22(scFv) alone was used as control. Non-
linear regression and IC50 calculations were performed using GraphPad Prism v5 software. Data 
represent three (H22(scFv)-ETA') and two (other ITs) independent experiments and are presented as 
means ± SD. Abbreviations: Ang, angiogenin; Gb, granzyme B; pM, picomolar; nM, nanomolar. 
 
 
 
III.1.3 Cytotoxicity of H22(scFv)-ETA' is mediated by apoptosis 
To confirm selective targeting and determine the cytotoxic mechanism against M1 
macrophages by H22(scFv)-based ITs, polarized murine macrophages were incubated with 
100 nM of H22(scFv)-ETA' (representing all tested ITs) for 72 h followed by staining with 
AnnexinV-FITC and PI as described (II.2.4.5). Only M1 macrophages showed a shift to 
the lower right corner of the dot plot representing the early apoptotic stage (Figure 12). 
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These results confirm that M1 macrophages are eliminated by H22(scFv)-ETA' through the 
induction of apoptosis. 
 
 
Figure 12. H22(scFv)-ETA' induces apoptosis in M1 macrophages. 
An apoptosis assay was carried out as described (II.2.4.5). (A) Dot plots of polarized macrophages after 
incubation with 100 nM H22(scFv)-ETA' for 72 h. (B) Quantitative analysis of dot blots shown in (A). 
Zeocin (0.5 mg/ml) was used as control. Data represent three independent experiments and are presented 
as means ± SD. Statistical analysis was carried out using a two-tailed unpaired Student’s t test. *p≤0.05, 
**p≤0.01, ***p≤0.001 compared with PBS (pH 7.4) control. 
 
 
 
III.1.4 Impact of IFN-γ on expression of hCD64 during M1-selective targeting 
The cell viability results shown above confirmed the M1-selective killing of macrophages 
by all tested H22(scFv)-based ITs (Figure 11). However, absolute depletion of the whole 
M1 population could not be achieved. Cell viability equilibrated at approximately 40–60% 
despite the increasing concentration of the therapeutic protein (a representative result for 
Gb-H22(scFv) is shown in Figure 13-A). To explain this phenomenon, hCD64tg polarized 
macrophages were incubated with 50 nM H22(scFv)-ETA' or H22(scFv) for 24, 48 and 
72 h and then analyzed for the expression of CD64 by flow cytometry (II.2.4.1.2). 
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H22(scFv) and PBS (pH 7.4) were used as controls. As early as 24 h after incubation with 
H22(scFv)-ETA' or H22(scFv), the expression of CD64 was strongly downregulated in all 
polarized macrophage populations (Figure 13-B) explaining why the M1 macrophages lost 
their sensitivity to even high concentrations of H22(scFv)-ETA'. To confirm that minimal 
hCD64 expression is required to make M1 macrophages susceptible to H22(scFv)-based 
ITs, M1 macrophages were incubated with H22(scFv)-ETA' for 24 h to downregulate the 
expression of hCD64 prior to boosting the cells with a supplementary 100 U/ml IFN-γ 
(PBS, pH 7.4 was used as a control). Although no additional H22(scFv)-ETA' was added 
to the cells, their viability was reduced significantly by boosting the expression of hCD64 
with IFN-γ (Figure 13-C). These results demonstrate that both the M1 polarization status 
and the expression of CD64 are prerequisites for the successful killing of M1 macrophages. 
Boosting the expression of hCD64 also illustrates the plasticity of polarized macrophages, 
which react sensitively to a changing environment.  
 
Figure 13. Boosting with IFN-γ restores the sensitivity of M1 macrophages to H22(scFv)-ETA'. 
(A) M1-specific elimination of macrophages by Gb-H22(scFv) with a steady state phase at higher 
concentrations (derived from Figure 11). (B) Polarized macrophages were incubated with 50 nM H22(scFv)-
ETA' or H22(scFv) for 24, 48 and 72 h (PBS, pH 7.4 was used as a control). Expression of hCD64 was 
analyzed by flow cytometry (section II.2.4.1.2). Relative expression levels were calculated as (MFIantibody – 
MFIisotype control)/MFIisotype control. Data represent three independent experiments and are presented as means ± 
SD. Statistical analysis was carried out using two-way ANOVA. *p≤0.05, **p≤0.01, ***p≤0.001 compared 
with the respective control at time point 0. (C) M1 macrophages were incubated with H22(scFv)-ETA' for 24 
h followed by the addition of 100 U/ml IFN-γ or PBS (pH 7.4). After incubation for a further 48 h, cell 
viability was assessed as described (II.2.4.4). Data represent two independent experiments and are presented 
as means ± SD. Statistical analysis was carried out using a two-tailed unpaired Student’s t test. *p≤0.05, 
**p≤0.01, ***p≤0.001 compared with non-boosted control. Abbreviations: pM, picomolar; nM, nanomolar. 
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III.1.5 Endosomal protease activity  
Although CD64 was expressed at different levels by all macrophage subpopulations 
(Figure 10), the lower numbers of CD64 molecules on M2 and M0 cells should 
nevertheless be sufficient to internalize an adequate number of toxin molecules. The 
sensitivity of M1 macrophages towards anti-CD64 ITs must therefore be determined by 
other factors, such as differential routing and processing after internalization.  
Generally, proteins that have been internalized by receptor-mediated endocytosis are 
routed through endosomes to the trans-Golgi network, where they can escape into the 
cytosol and confer toxicity. However, the stability of proteins within the endosomes is a 
critical aspect because these compartments contain many proteases. If there is high 
endosomal protease activity, internalized proteins fail to escape from the endosomes and 
are degraded. Therefore, the endosomal protease activity of polarized macrophages was 
assessed using customized silica beads as described in section II.2.4.6 (Figure 14).  
 
 
Figure 14. Design of silica beads for the assessment of endosomal protease activity. 
DQ-Green-coated silica beads were prepared as described (II.2.4.6).  
 
Kinetic measurements of green fluorescence revealed that M1 macrophages have a 
strongly diminished endosomal protease activity compared with M0 and M2 macrophages 
(represented by the slope of the linear phase). Furthermore, the efficiency with which the 
ovalbumin-coated beads were taken up by phagocytosis (represented by the plateau value) 
was highest in M2 macrophages followed by M0 and then M1 macrophages, in line with 
the abundance of CD206 (Figure 15). 
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Figure 15. M1 macrophages have low endosomal protease activity. 
The endosomal protease activity of polarized macrophages was measured as described (II.2.4.6). (A) 
Kinetic measurement of green fluorescence produced by the proteolytic separation of DQ Green 
molecules from ovalbumin. (B) Quantitative analysis of relative protease activity in polarized 
macrophages. Curve slopes obtained from (A) were used as an indirect measurement of the relative 
protease activity. The protease activity of M0 macrophages was normalized to 100. Data represent three 
independent experiments and are presented as means ± SD. Statistical analysis was carried out using 
one-way ANOVA. *p≤0.05, **p≤0.01, ***p≤0.001. 
 
To confirm the functional involvement of proteases in this process, polarized 
macrophages were pre-incubated with Calpain inhibitor (Sigma), a specific inhibitor of 
cathepsin B and L, prior to the determination of endosomal protease activity. The Calpain 
inhibitor reduced the protease activity of M1 and M2 but not M0 macrophages (Figure 16), 
again possibly reflecting the residual metabolic activity of M0 macrophages (III.1.2.3.2).   
 
M0 M1 M2
0
50
100
150
200
250
PBS
Calpain Inhibitor
*
***
***
R
el
at
iv
e 
pr
ot
ea
se
 a
ct
iv
ity
   
[-]
 
Figure 16. Calpain inhibitor reduces the endosomal protease activity of M1 and M2 cells. 
Polarized macrophages were pre-incubated with 5 µM of Calpain inhibitor (Sigma) for 1 h at 37°C 
followed by the measurement of endosomal protease activity as described (II.2.4.6). Data represent two 
independent experiments and are presented as means ± SD. Statistical analysis was carried out using a 
two-tailed unpaired Student’s t test. *p≤0.05, **p≤0.01, ***p≤0.001 compared with PBS (pH 7.4) 
control. 
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Finally, it was demonstrated that the high endosomal protease activity of M2 
macrophages conferred resistance against H22(scFv)-based ITs. Indeed, pre-incubation 
with the Calpain inhibitor overrode the resistance of M2 macrophages to H22(scFv)-ETA' 
as shown in Figure 17. In M0 and M1 macrophages, the Calpain inhibitor had no 
significant impact compared to the control (Figure 11). 
 
 
Figure 17. Calpain inhibitor overrides the resistance of M2 macrophages to H22(scFv)-ETA'. 
Polarized macrophages were pre-incubated with 5 µM of Calpain inhibitor for 1 h at 37°C followed by 
the addition of H22(scFv)-ETA'. Cells were incubated for 72 h and viability was determined as described 
(II.2.4.4). Non-linear regression and IC50 values were calculated using GraphPad Prism v5 software. 
Data represent three independent experiments and are presented as means ± SD. Abbreviations: pM, 
picomolar; nM, nanomolar. 
 
 
 
III.1.6 Plasticity of polarized macrophages 
Macrophages are highly flexible and plastic cells that can react rapidly to changes in the 
microenvironment. Because M1 and M2 macrophages play opposite roles during 
inflammation, the conversion of M1 to M2 cells by in situ re-polarization within inflamed 
tissues could offer a potential strategy to shift the M1/M2 ratio towards an anti-
inflammatory status. Proof of concept for this approach was provided by using IFN-γ and 
IL-4 as re-polarizing stimuli and measuring the degree of re-polarization by monitoring 
selected surface markers (Figure 18) and soluble cytokines (Figure 19). Re-polarization 
assays were carried out with murine hCD64tg macrophages as described (II.2.4.3). hCD64, 
CD14 and CD36 were used as representative M1 markers, whereas CD273, CD301 and 
CD206 were used as M2 markers. The re-polarization of M1 macrophages by IL-4 resulted 
in the downregulation of all three M1 markers, whereas the expression of two M2 markers 
(CD206 and CD301) was increased. In contrast, the re-polarization of M2 macrophages 
with IFN-γ induced the expression of all three M1 markers and suppression of the M2 
marker CD273. 
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Figure 18. Macrophage re-polarization modulates the expression of surface receptors. 
The re-polarization of polarized macrophages was carried out as described (II.2.4.3). Selected surface 
receptors were analyzed by flow cytometry (section II.2.4.1.2). M1/M2 ratio > 0 = upregulation in M1 
cells; M1/M2 ratio < 0 = upregulation in M2 cells. Data represent two independent experiments and are 
presented as means ± SD. Abbreviations: MC, medium change. 
 
The surface receptor profiles induced respectively by IFN-γ and IL-4 provided the first 
evidence that re-polarizing macrophages can be confirmed on the level of surface 
receptors. However, the crucial pathogenic activity of M1 macrophages during chronic 
inflammation is the production of pro-inflammatory cytokines that amplify the 
inflammatory response by activating Th1 cells (Figure 1). Therefore, the supernatants of 
re-polarized macrophages were analyzed for the critical soluble cytokines IL-12 and IL-6.  
The production of IL-12 by M1 cells was completely abrogated by re-polarization with 
IL-4 and the production of IL-6 was reduced, albeit to a lesser extent. In contrast, the 
expression of IL-12 and IL-6 were strongly induced in M2 cells by the addition of IFN-γ.  
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Figure 19. Macrophage re-polarization modulates the cytokine profile.  
The re-polarization of polarized macrophages was carried out as described (II.2.4.3). Supernatants were 
analyzed for IL-12 and IL-6 by FlowCytomix as described (II.2.4.2). Data represent three independent 
experiments and are presented as means ± SD. Statistical analysis was carried out using one-way 
ANOVA. *p≤0.05, **p≤0.01, ***p≤0.001 compared with the respective control polarization (24 h IFN-γ 
for M1 and IL-4 for M2). Abbreviations: MC, medium change. 
 
As well as phenotypic plasticity, the functional plasticity of polarized macrophages was 
demonstrated by reversing their sensitivity towards H22(scFv)-ETA'. The stimulation of 
previously sensitive M1 macrophages with IL-4 conferred resistance towards the IT, 
whereas previously resistant M2 macrophages became sensitive towards H22(scFv)-ETA' 
following exposure to IFN-γ (Figure 20). These data illustrate that already-polarized 
macrophages can be skewed towards other phenotypes with diverse functions. IFN-γ and 
IL-4 provide proof of principle that the re-polarization of polarized macrophages is a 
suitable approach for immunomodulation.  
 
Figure 20. Re-polarization inverts the sensitivity of macrophages towards H22(scFv)-ETA'. 
The re-polarization of polarized macrophages was carried out as described (II.2.4.3). After the addition 
of H22(scFv)-ETA', cells were incubated for 72 h and viability was determined as described (II.2.4.4). 
Non-linear regression and IC50 values were calculated using GraphPad Prism v5 software. Data represent 
three independent experiments and are presented as means ± SD. Abbreviations: pM, picomolar; nM, 
nanomolar. 
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III.2 Generation of H22(scFv)-MAP 
III.2.1 Cloning of H22(scFv)-MAP 
Ready-to-use plasmid DNA (pCMV6-XL5-MAP) containing the MAP open reading frame 
was obtained from Origene. After amplification (Figure 21/ lane 1) using gene-specific 
primers #1 and #2 (II.2.1.10) the PCR product was subcloned into the EcoRI/HindIII 
restriction sites of a pUC18 plasmid.  
 
 
Figure 21. Amplification of the MAP open reading frame and transfer to the pMT vector. 
The MAP sequence was amplified from the pCMV6-XL5-MAP template (Origene) by PCR yielding a 
1195-bp product (lane 1). After subcloning into a pUC18 plasmid and two subsequent mutagenesis PCR 
steps, the mutated MAP was excised using the NotI/BlpI restriction sites and ligated into the bacterial 
expression vector pMT, which already contained the sequence for H22(scFv). Successful cloning was 
verified by control digestion with HindIII (lane 2) and separation of DNA by agarose gel electrophoresis 
(II.2.1.7). M, 2-log-DNA Ladder. Abbreviations: bp, base pairs. 
 
Optimal annealing temperature and cycling conditions were determined empirically as 
summarized in Table 13. 
 
Table 13. Optimal cycling conditions for amplification of the MAP open reading frame. 
Cycle Step Temperature Time  
Initial Denaturation 98°C 3 s  
Denaturation 98°C 10 s  
Annealing  58°C 30 s x 35 
Extension 72°C 45 s  
Final Extension 72°C 5 min  
Pause 4°C Hold  
 
Two subsequent mutagenesis PCR steps using the primer pairs #3+4 and #5+6, 
respectively, resulted in the removal of two phosphorylation sites critical for the efficient 
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binding of MAP to microtubules. The successful introduction of point mutations was 
verified by sequencing (II.2.1.13) before the sequence was excised using the NotI/BlpI 
restriction sites and ligated into a appropriately linearized pMT vector, which already 
contained the sequence for H22(scFv). Successful ligation was confirmed by control 
digestion with HindIII yielding two fragments of 5617 and 1629 bp (Figure 21/ lane 2). An 
overview of the cloning strategy is provided in Figure 22. 
 
 
Figure 22. Cloning strategy of H22(scFv)-MAP. 
pCMV6-XL5-MAP was purchased from Origene. The MAP open reading frame was amplified and 
subcloned into a pUC18 vector for two subsequent mutagenesis PCR steps. Two point mutations (X) 
were introduced leading to the removal of two critical phosphorylation sites. Finally, the mutated MAP 
sequence was cloned into the bacterial expression vector pMT, which already contained the sequence for 
H22(scFv). Abbreviations: MAP, microtubule-associated protein tau; ORF, open reading frame. 
 
 
 
III.2.2 Expression and purification of H22(scFv)-MAP 
H22(scFv)-MAP was expressed in E. coli BL21(DE3) cells using the periplasmic stress 
expression protocol (II.2.1.3) and a His-10 tag was used for protein enrichment by IMAC. 
A yield of up to 1 mg of purified protein per liter of E. coli culture was achieved. After 
purification by IMAC (II.2.2.1) and SEC (II.2.2.2), the enrichment and identity of 
H22(scFv)-MAP were confirmed by SDS-PAGE, staining with Coomassie Brilliant Blue 
G-250 (II.2.3.2) and western blot (II.2.3.3). Despite the SEC step which should separate 
proteins based on differences in size, the preparation still contained free scFv as shown in 
Figure 23/ lane 1. Whether degradation into the free scFv and the full-length protein 
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occurred during expression, protein extraction or protein purification is unknown. Finally, 
the identity of the full-length protein was confirmed by western blot using anti-Tau 
Monoclonal Antibody (HT7) from Thermo Scientific (Figure 23/ lane 2). The theoretical 
molecular weight of H22(scFv)-MAP is 71.6 kDa. 
 
 
Figure 23. SDS-PAGE and western blot analysis of H22(scFv)-MAP. 
H22(scFv)-MAP was purified by IMAC (II.2.2.1) and SEC (II.2.2.2). The purity was assessed by SDS-
PAGE (II.2.3.2) followed by staining with Coomassie Brilliant Blue G-250 (lane 1). Protein identity was 
verified by western blot (lane 2) using anti-Tau Monoclonal Antibody (1:25,000, Thermo Scientific) 
(II.2.3.3) detected with an alkaline phosphatase-conjugated anti-mouse-IgG mAb (1:5,000; Sigma) 
followed by staining with NBT/BCIP substrate (Life Technologies). M, pre-stained broad range protein 
marker (New England BioLabs). Abbreviations: kDa, kiloDalton. 
 
 
III.2.3 Binding of H22(scFv)-MAP to target cells 
In preparation for targeting experiments, the ability of purified H22(scFv)-MAP to bind 
target cells was tested by flow cytometry (II.2.4.1.1). In the initial in vitro experiments, 
hCD64-expressing cell lines HL-60 and U937 were used because both cell lines are 
precursors of macrophages and therefore represent a valuable in vitro model of 
macrophages. H22(scFv)-MAP was also tested for binding to polarized macrophages 
isolated from hCD64tg mice. Successful binding was confirmed on all the target cells and 
there was no binding to hCD64– L540cy cells (Figure 24). 
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Figure 24. Binding analysis of H22(scFv)-MAP. 
The binding of purified H22(scFv)-MAP to hCD64+ cell lines HL-60 and U937, and polarized murine 
hCD64tg macrophages, was tested by flow cytometry (II.2.4.1.1). HL-60 and U937 cells were stimulated 
with 50 U/ml IFN-γ 24 h prior to analysis. L540cy cells (CD64-) and H22(scFv)-ETA' were used as 
controls.  
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III.2.4 Proliferation-dependent cytotoxicity of H22(scFv)-MAP 
The cytotoxicity of H22(scFv)-MAP was also tested initially on HL-60 cells. Because the 
effector protein MAP was anticipated to interfere with mitosis, the proliferation-dependent 
effects of H22(scFv)-MAP were investigated. HL-60 cells are known to proliferate 
continuously in suspension culture in vitro. However, proliferation is arrested following 
stimulation with PMA but not IFN-γ (Figure 25). This property makes HL-60 cells a 
suitable system for investigation of proliferation-dependent H22(scFv)-MAP cytotoxicity.  
 
 
Figure 25. Stimulation-dependent proliferation of HL-60 cells. 
Stimulation-dependent proliferation of HL-60 cells was investigated by (A and B) staining with PI and 
(C) cell counting (II.2.4.8). Data represent two independent experiments and are presented as means ± 
SD. Statistical analysis was carried out using one-way ANOVA. *p≤0.05, **p≤0.01, ***p≤0.001. 
Abbreviations: G0/G1/S/G2/M, cell cycle phases; PMA, phorbol 12-myristate 13-acetate. 
 
H22(scFv)-MAP was able to induce apoptosis only in proliferating cells (unstimulated 
or stimulated with IFN-γ), leaving non-proliferating cells (stimulated with PMA) 
unaffected. This contrasts with the activity of H22(scFv)-ETA', which was able to kill non-
proliferating cells, albeit to a lesser extent (Figure 26). 
 
 
 
Results 
55 
 
 
Figure 26. H22(scFv)-MAP selectively kills IFN-γ activated (proliferating) HL-60 cells. 
Cell viability assays were carried out as described (II.2.4.4). HL-60 cells were stimulated with either 50 
U/ml IFN-γ or 20 ng/ml PMA for 24 h prior to the addition of H22(scFv)-MAP or H22(scFv)-ETA'. 
Unstimulated cells were used as controls. Non-linear regression and IC50 values were calculated 
GraphPad Prism v5 software. Data represent two independent experiments and are presented as means ± 
SD. Abbreviations: PMA, phorbol 12-myristate 13-acetate; pM, picomolar; nM, nanomolar. 
 
The proliferation-dependent cytotoxicity of H22(scFv)-MAP was ultimately confirmed 
using primary macrophages. Peritoneum-derived murine macrophages and PBMC-derived 
human macrophages are known to cease proliferating following isolation and cultivation in 
vitro. Therefore, non-proliferating macrophages were completely unaffected by 
H22(scFv)-MAP, in contrast to other H22(scFv)-based ITs (compare Figure 27 and Figure 
11).  
 
Figure 27. H22(scFv)-MAP does not affect non-proliferating primary macrophages. 
Peritoneal macrophages isolated from hCD64tg mice and PBMC-derived human macrophages were 
cultured in vitro to arrest proliferation. After polarization, the cytotoxicity of H22(scFv)-MAP was 
determined as described (II.2.4.4). Data were analyzed using GraphPad Prism v5 software. Data 
represent three independent experiments and are presented as means ± SD. Abbreviations: nM, 
nanomolar. 
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III.2.5 H22(scFv)-MAP cytotoxicity is mediated by apoptosis 
H22(scFv)-MAP was tested for its ability to induce apoptosis in proliferating HL-60 cells 
as described (II.2.4.5). The number of early and late apoptotic cells was significantly 
increased by H22(scFv)-MAP compared with cells incubated with PBS (pH 7.4) or 
H22(scFv) alone. There was no impact on hCD64– L540cy cells (Figure 28). 
 
 
Figure 28. H22(scFv)-MAP induces apoptosis in HL-60 cells. 
An apoptosis assay was carried out as described (II.2.4.5). (A) Dot plots of HL-60 cells after incubation 
with 50 nM H22(scFv)-ETA', H22(scFv)-MAP, or H22(scFv) for 24 h, with hCD64– L540cy cells as a 
control. (B) Quantitative analysis of dot blots shown in (A). Data present three independent experiments 
and are presented as means ± SD. Statistical analysis was carried out using two-way ANOVA. *p≤0.05, 
**p≤0.01, ***p≤0.001 compared with the respective PBS (pH 7.4) control. 
 
 
 
III.2.6 Stabilization of microtubules by H22(scFv)-MAP 
Apoptosis can be induced by changing the dynamics of microtubule polymerization either 
by stabilizing (e.g. paclitaxel) or destabilizing (e.g. nocodazole). The effector protein MAP 
was expected to intervene in mitosis by binding to and stabilizing microtubules. To 
investigate the mechanism of H22(scFv)-MAP cytotoxicity, a tubulin polymerization assay 
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was carried out (II.2.4.7). H22(scFv)-MAP (400 nM) was capable of stabilizing 
microtubules efficiently, thus promoting the polymerization process. General tubulin 
buffer and paclitaxel were used as controls (Figure 29). 
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Figure 29. H22(scFv)-MAP promotes tubulin polymerization. 
A tubulin polymerization assay was carried out as described (II.2.4.7). General tubulin buffer and 
paclitaxel (10 µM) were used as controls. H22(scFv)-MAP (400 nM) was able to stabilize microtubules. 
Vmax values were calculated using the slope of the linear phase. H22(scFv)-MAP proved effective in 
promoting tubulin polymerization. Abbreviations: mE, milli-extinction. 
 
III.3 CD64-mediated selective elimination of M1 macrophages in vivo 
III.3.1 H22(scFv)-ETA' and H22(scFv)-MAP selectively kill M1 macrophages  
Having confirmed the M1-specific elimination of polarized macrophages in vitro, 
H22(scFv)-ETA' and H22(scFv)-MAP were then tested in a hCD64tg SLS-induced 
cutaneous inflammation mouse model in vivo. The repetitive epicutaneous administration 
of SLS, a skin irritating agent, causes mice to develop a chronic skin inflammation. The 
inflammation can be resolved using a full-length antibody against hCD64 coupled to the 
plant toxin Ricin A [85]. However, little is known about the selectivity of this treatment 
strategy for M1 macrophages. Because M2 macrophages also express hCD64, this anti-
inflammatory cell population could also be adversely affected. After the induction of 
cutaneous inflammation, mice received three consecutive intradermal injections containing 
1 µM of H22(scFv)-ETA' or H22(scFv)-MAP, with PBS (pH 7.4) used as control 
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(II.2.5.3). Finally, skin biopsies were analyzed by IHC. CD14 and hCD64 were used as M1 
markers, whereas M2 macrophages were detected using CD206 and CD301. 
Both H22(scFv)-ETA' and H22(scFv)-MAP reduced the number of M1 macrophages as 
shown by the reduction of CD14+ and hCD64+ cells. In contrast, the number of M2 cells 
increased as shown by the detection of CD206+ and CD301+. H22(scFv)-MAP increased 
the number of M2 cells even more than H22(scFv)-ETA', confirming the selectivity of 
H22(scFv)-based therapeutic proteins against M1 macrophages (Figure 30).  
 
 
Figure 30. Elimination of M1 macrophages by H22(scFv)-ETA' and H22(scFv)-MAP in vivo. 
Sections from inflamed mouse skin were prepared and stained for specific markers by IHC (II.2.4.10). 
Quantitative analysis was carried out using Photoshop CS5 Extended software. The relative cell number 
obtained for PBS group (n=5) was normalized to 100% and compared with the treated group (n=5). 
Values are presented as means ± SEM. Statistical analysis was carried out using a two-tailed unpaired 
Student’s t test. *p≤0.05, **p≤0.01, ***p≤0.001 compared with untreated control. 
 
Representative immunohistochemical images are shown in Figure 31. 
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Figure 31. Immunohistochemical analysis of mouse skin sections. 
Tissue sections were prepared as described (II.2.4.10). Images were acquired and analyzed as described 
(II.2.4.11). Representative results are shown. Examples of stained cells are indicated by arrows. 
Objective: 10x.  
 
Reduction of M1 macrophages at the site of inflammation led to an M2-promoting 
microenvironment, which finally resulted in a shifted M1/M2 ratio (Figure 32). 
 
 
Figure 32. H22(scFv)-ETA' and H22(scFv)-MAP shift the M1/M2 ratio. 
M1/M2 ratios were calculated on the basis of the quantitative results shown in Figure 30. hCD64 and 
CD14 were used as M1 markers. CD206 and CD301 were used as M2 markers. 
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III.3.1.1 Local proliferation of M1 macrophages in vivo 
The in situ proliferation of tissue macrophages is a matter of debate. Whether only blood 
monocytes proliferate and become resting macrophages following the infiltration of 
tissues, or whether mature tissue macrophages are also able to proliferate in situ is not fully 
understood. However, the successful elimination of M1 macrophages by H22(scFv)-MAP 
in vivo indicates that polarized macrophages in inflamed tissues do proliferate, given that 
MAP is cytotoxic only towards proliferating cells (III.2.4). To provide direct evidence, 
tissue sections from inflamed skin were double-stained for hCD64 (M1 marker) and Ki67 
(proliferation marker) as described (II.2.4.9). Images were acquired by 
immunofluorescence microscopy. Two representative images are shown in Figure 33. 
Among many Ki67+/hCD64- cells, which could be of any other cell type found in the skin 
(e.g., keratinocytes, T cells or dendritic cells), double-positive (Ki67+/hCD64+) cells were 
also detected confirming that M1 macrophages proliferate in vivo. 
 
 
Figure 33. Tissue M1 macrophages proliferate in vivo. 
Sections of inflamed mouse skin were double-stained for a proliferation marker (Ki67; green) and an M1 
marker (hCD64; red) as described (II.2.4.9). Images were acquired by confocal microscopy. Some 
double-positive cells are indicated by arrows. Two representative sections are shown. Objective: 40x (+ 
zoom). 
 
 
Results 
61 
 
III.3.2 Selective elimination of M1 macrophages in a human skin biopsy  
To demonstrate the clinical relevance of M1-targeted therapy for chronic inflammatory 
diseases, a skin biopsy from a patient with atopic dermatitis (chronically inflamed skin) 
was treated with H22(scFv)-ETA' ex vivo. Skin sections stained with hematoxylin and 
eosin (pictures kindly provided by Dr. Verena von Felbert, University Hospital Aachen, 
Germany) clearly showed the massive infiltration of immune cells. In line with the data 
obtained in the mouse model, H22(scFv)-ETA' proved effective in reducing the number of 
M1 macrophages (CD14), while significantly increasing the number of M2 macrophages 
(CD206 and CD301) (Figure 34 and Figure 35). Consequently, the M1/M2 ratio was 
shifted towards M2 (Figure 36). 
 
 
Figure 34. Elimination of M1 macrophages in a skin biopsy from an atopic dermatitis patient. 
A human skin biopsy was treated ex vivo with 1 µM of H22(scFv)-ETA' for 24 or 48 h (II.2.5.2). An 
untreated biopsy was frozen directly after punching. Another untreated biopsy was incubated in 
complete medium only and used as a control. After treatment, skin sections were prepared and stained 
for specific markers by IHC. Quantitative analysis was carried out using Photoshop CS5 Extended 
software. The relative cell number obtained for the untreated biopsy was normalized to 100%. Values are 
presented as means ± SD. Statistical analysis was carried out using a two-tailed unpaired Student’s t test. 
*p≤0.05, **p≤0.01, ***p≤0.001 compared with untreated control or as indicated. 
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Figure 35. Immunohistochemical analysis of human skin sections. 
Tissue sections were prepared as described (II.2.4.10). Images were acquired and analyzed as described 
in II.2.4.11. Representative results are shown. Stained cells are indicated by arrows. Objective: 10x. HE, 
hematoxylin & eosin staining of untreated skin. 
 
 
Figure 36. Treatment with H22(scFv)-ETA' shifts the M1/M2 ratio towards M2.  
M1/M2 ratios were calculated on the basis of the quantitative results shown in Figure 34. CD14 was 
used as an M1 marker. CD206 and CD301 were used as M2 markers. 
 
 
 
III.3.2.1 Elimination of M1 macrophages changes the cytokine profile 
Soluble cytokines have far-reaching effects on inflammation and influence more than the 
polarization of macrophages and the stimulation of T cells. Whereas the polarization of 
macrophages is a localized inflammatory response, the stimulation of T cells may have 
systemic effects. Therefore, targeting M1 macrophages may not only shift the M1/M2 
ratio, but also change the cytokine profile in the microenvironment. Therefore, the 
supernatants of human skin biopsies before and after treatment were analyzed for the 
presence of critical cytokines by FlowCytomix (II.2.4.2). Two cytokines, the pro-
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inflammatory IL-6 and the anti-inflammatory IL-10, could be determined. In agreement 
with the results obtained for surface receptors, IL-6 production was strongly reduced 
following 24 h of treatment with H22(scFv)-ETA'. In sharp contrast, IL-10 production was 
significantly increased, whereas no IL-10 was detected in the untreated control (Figure 37). 
This result emphasizes the anti-inflammatory impact of M1-targeted therapy, because this 
approach influences not only the balance between pro-inflammatory and anti-inflammatory 
macrophages but also the cytokine profile, which is shifted towards an overall anti-
inflammatory state. Because there can be no influx of new (presumably M0) macrophages 
in this system, the increased abundance of M2 macrophages and the resulting shift in the 
M1/M2 ratio can only be explained by M1 macrophages switching phenotype to M2. 
 
 
Figure 37. Cytokine profiles of supernatants derived from human skin biopsies. 
After the treatment of human skin biopsies ex vivo, supernatants were collected and analyzed for soluble 
cytokines by FlowCytomix (II.2.4.2). Data represent two independent experiments and are presented as 
means ± SD. Statistical analysis was carried out using one-way ANOVA. *p≤0.05, **p≤0.01, 
***p≤0.001 compared with untreated control. Abbreviations: b.d., below detection limit; M, molar. 
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IV Discussion 
 
Macrophages are an essential component of the innate immune system and key players in 
the regulation of inflammation. They are also involved in further physiological processes 
such as tissue remodeling. Although they have been studied for many years, the division of 
these cells into distinct M1 and M2 subpopulations has been investigated only recently. 
The dynamic M1 vs. M2 ratio plays an important role in the proper development and 
resolution of inflammation. M1 cells dominate during the early inflammatory phase, 
whereas M2 cells dominate in the late/repair phase. In chronic disease, this normal 
progression is arrested during the M1 dominant phase, leading to a chronic inflammatory 
response and tissue damage.  
In this thesis, M1-specific therapy using hCD64-targeted ITs was investigated. First, 
polarized macrophages were analyzed for the expression of distinct surface markers and 
soluble cytokines. In vitro targeting experiments using H22(scFv)-based ITs confirmed the 
M1-specific elimination of polarized murine and human macrophages. Finally, these 
findings were confirmed in vivo in a hCD64tg mouse model and ex vivo using a human 
skin biopsy from a patient with atopic dermatitis. A new fully human CFP comprising 
H22(scFv) and MAP was also developed and characterized in vitro and in vivo for its 
ability to target and kill CD64+ cells. 
 
IV.1 The role of polarized macrophages in health and disease 
The resolution of inflammation, tissue remodeling and repair are interconnected processes 
that are closely regulated by macrophages. For simplicity, macrophages have two main 
roles during these processes: (1) tissue damage and initiation of inflammation through the 
production of pro-inflammatory cytokines, which attract further effector cells required for 
resolution; and (2) the induction of resolution and tissue repair through the removal of 
debris and apoptotic neutrophils, the production of vascularization-promoting factors, and 
the promotion of fibroblast and keratinocyte growth. Concomitant with the growing 
knowledge on macrophage polarization, it becomes more obvious that the transition 
between the M1-driven initiation and the M2-mediated resolution of inflammation is 
critical.  
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In the last few years, signaling molecules responsible for the obligatory M1-M2 switch 
during inflammation have been identified, many of which contribute towards the pathology 
of autoimmune and chronic inflammatory disorders. In a murine model of SLE, for 
instance, sustained M1 polarization is caused by Notch signaling [128], but when M1 
macrophages were skewed towards an M2-like phenotype using the acute-phase serum 
protein amyloid P, the SLE symptoms were ameliorated [129]. Similar M1 pathology is 
associated with cardiovascular diseases such as atherosclerosis [130]. However, M2 
macrophages do not always play a positive role. In the lung and other parenchymal organs, 
fibrosis may be induced by TGF-β-stimulated M2-like macrophages [131]. Lipid 
mediators, such as prostaglandins, have been shown to play a central role in the regulation 
of inflammation [132, 133]. Whereas prostaglandins E2 and D2 confer pro-inflammatory 
activity during acute inflammation, the same molecules promote the biosynthesis of anti-
inflammatory lipid mediators including lipoxins, resolvins and protectins during the 
resolution phase. Indeed, some of these lipid mediators are produced by macrophages. For 
example, prostaglandin E2 and prostaglandin E synthase, the terminal enzyme in the 
prostaglandin E2 synthesis pathway, are upregulated in M1 macrophages [132, 134, 135]. 
Conversely, M2-promoting stimuli (e.g. IL-4 or IL-13) downregulate the expression of this 
enzyme [136].  
Another signaling molecule that may be involved in the transition between M1 and M2 
cells is cAMP. In a murine model of inflammation, cAMP was shown to inhibit M1 
polarization leading to a hybrid macrophage phenotype during the resolution phase [137]. 
Furthermore, differences in iron metabolism within polarized macrophages may explain 
non-healing chronic venous ulcers (CVUs) in humans. The iron overload found in CVUs 
led to the persistence of M1 macrophages, which ultimately resulted in ROS-mediated 
DNA damage and defective tissue repair [9, 138]. Further examples of the characteristic 
M1/M2 dichotomy were demonstrated in models of ischemic heart and kidney disease and 
hindlimb ischemia [139-142].  
As well as their roles in tissue remodeling, macrophages also participate in homeostasis 
during oncogenesis, embryonic development and in selected tissues in adults. Intriguingly, 
polarization plays an important role during these physiological processes. Macrophages 
derived from murine embryos, human fetal liver and embryonic stem cells display an M2-
like phenotype [143, 144]. At the fetal-maternal interface, the presence of 
immunosuppressive M2-like macrophages that communicate with adjacent NK cells and 
Discussion 
66 
 
Tregs [145] demonstrates that macrophages not only promote homeostatic remodeling, but 
also create a tolerogenic environment between the mother and child [146-148]. There is 
also strong evidence that macrophages contribute to the development of several organs 
including bone, mammary gland, nervous system and pancreas [149]. 
In this thesis, pathological M1 macrophages that promote chronicity and hinder the 
resolution of inflammation were successfully eliminated using hCD64-targeted ITs. Most 
interestingly, the pinpoint elimination of M1 macrophages also converted the 
microenvironment into an anti-inflammatory and M2-promoting milieu. These results were 
achieved in both a transgenic mouse model and a human skin biopsy derived from a patient 
with atopic dermatitis. Because new and presumably M0 macrophages could not be 
recruited in the last system, the increased abundance of M2 cells and the resulting M1/M2 
ratio shift can only be explained by M1/M0 macrophages switching phenotype to M2 
macrophages in situ. Although the human data were obtained for only one example of a 
chronic skin disease (atopic dermatitis), the lesson learned from this study may be 
transferable to diverse immunological diseases featuring a disrupted M1/M2 ratio such as 
rheumatoid arthritis, diabetes, multiple sclerosis or chronic wounds.  
The analysis of soluble cytokines showed that the M1/M2 ratio shift affected not only 
the surface phenotype of macrophages but also the profile of secreted cytokines, resulting 
in an overall anti-inflammatory milieu. This is particularly interesting in the light of 
systemic T cell stimulation as opposed to the rather localized inflammatory response 
produced by macrophages. M1 and M2 macrophages are tightly associated with the 
development of Th1 and Th2 responses, respectively [19, 20, 135]. M2 (but not M1) 
macrophages were also found to induce the differentiation of Tregs with a striking 
suppressive phenotype. This process required cell-cell contact and was dependent on the 
expression of membrane-bound TGF-β1 [150]. In addition to T cells, polarized 
macrophages also interact with NK cells, e.g. both M1 and M2 macrophages can trigger 
the degranulation of NK cells whereas only M1 cells infected with Human 
cytomegalovirus induced the production of the anti-viral cytokine IFN-γ [151]. Different 
polarized macrophages therefore take part in essential biological processes under both 
physiological and pathological conditions. In addition to inflammation and tissue repair, 
polarized macrophages contribute to the regulation of several other processes: (1) fighting 
infections by bacteria, viruses and parasites; (2) regulation of metabolic processes; (3) 
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immunoregulation in the context of cancer; and (4) participation in the development of 
allergic reactions.  
In general, bacterial infections are characterized by the presence of M1 macrophages, 
which are not only responsible for the recruitment of other effector cells by secreting 
soluble cytokines, but also contribute to resistance against intracellular pathogens by 
producing ROS and RNI. This has been demonstrated for several intracellular bacterial 
pathogens including Salmonella typhi, S. typhimurium [152] and Listeria monocytogenes 
[153]. The early stages of infection with Mycobacterium tuberculosis, M. ulcerans and M. 
avium [154-156] are also associated with the presence of M1 macrophages. However, the 
uncontrolled persistence of M1 cells in combination with acute and, under normal 
conditions, harmless infections with bacteria such as E. coli, can lead to gastroenteritis, 
sepsis and neonatal meningitis [157]. In contrast to acute infections, chronic infections are 
characterized by M2 dominance, which reflects M1-M2 switching events that occur during 
the transition from acute to chronic infection. Even though switching from M1 to M2 
prevents tissue damage and protects the organism from uncontrolled M1/Th1-dependent 
inflammation, the loss of M1 macrophages during bacterial infection can promote the 
amplification of incumbent intracellular pathogens [158-161]. 
Macrophages are also involved in the propagation of Human immunodeficiency virus 1 
(HIV-1). Unlike myeloid dendritic cells, which capture HIV-1 at sites of mucosal entry 
followed by migration to lymph nodes and the transmission of phagocytosed virions to 
CD4+ T cells [162, 163], resident macrophages play a local role in the transmission of 
HIV-1 [164]. Following infection by CCR5-dependent viruses, macrophages accumulate 
de novo synthesized virions in subcellular compartments and finally infect susceptible 
CD4+ T cells [164-167]. Only recently, M1 and M2a cells were shown to play distinct 
roles in HIV-1 transmission [168]. First, replication of the virus was inhibited in both M1 
and M2 cells compared with non-polarized macrophages (M0). However, M2 macrophages 
showed more potent HIV-1 binding and transmission to T cells despite low CD4 
expression, which was facilitated by the upregulation of CD209. Based on these results, 
M2 macrophages are considered as HIV-1-transmitting macrophages. In contrast, M1 
macrophages can be defined as HIV-1-resistant macrophages because: (1) they support low 
levels of virus replication; (2) the expression of CD209 is strongly downregulated; and (3) 
they express intracellular apolipoprotein B mRNA editing enzyme, which was recently 
classified as an antiviral defense protein [169-171]. Although M2 macrophages are 
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burdened with the pathological transmission of HIV-1, they play a pivotal role in 
mediating the resolution of inflammation and in the reduction of epithelial lung damage in 
bronchiolitis induced by Respiratory syncytial virus [172].    
The course of infection with parasites is comparable to that described for bacteria. 
Whereas Th1-mediated M1 polarization typifies the early phase of infection with e.g. 
Taenia crassiceps, Schistosoma mansoni and Trypanosoma congolense, the Th2-driven 
M2 polarization of macrophages is dominant in the late phase [173-175]. Furthermore, the 
NF-κB p50-dependent predominance of M2 macrophages during the chronic phase of 
Taenia crassiceps infection was shown to confer protection by reducing the pathogen load 
[176]. In another study, M2 macrophages were shown to promote the resolution of 
inflammation and mediate acute wound healing in a mouse model of acute lung injury 
infected with the intestinal nematode parasite Nippostrongylus brasiliensis [177].  
Diabetes types 1 and 2, obesity-induced insulin resistance, and metabolic syndrome are 
all associated with chronic inflammation [178]. Adipose tissue macrophages (ATMs) are 
key players in the development of metabolic disorders. Diabetes type 1 is an autoimmune 
disease caused by the selective destruction of the insulin-producing β cells in pancreatic 
islets of Langerhans, which finally results in the dysregulation of glucose homeostasis 
[179]. Selective destruction of β cells is achieved by M1-type ATMs and CD4+CD8+ 
T cells, which infiltrate the islets first and produce high levels of IL-6, TNF-α, IL-1β, ROS 
and RNI [180, 181]. In obesity (diabetes type 2, metabolic syndrome), the number of 
ATMs is increased from 10% of all adipose tissue cells to more than 50%, which also 
correlates with the degree of obesity [7]. The ATMs of obese individuals shift their 
phenotype from M2 (CD206+, CD301+, Arg1+) to M1 (NOS2+, CD11c+), and produce pro-
inflammatory cytokines such as IL-6, TNF-α and IL-1β [7, 56, 182, 183]. In turn, these 
factors antagonize the effect of leptin and adiponectin, both of which promote insulin 
sensitivity [183, 184]. Interestingly, adipose tissue T cells pass through a similar process of 
switching. Whereas lean individuals have a dominant population of Th2 and Treg cells, 
Th1 and CD8+ cells are dominant in obese individuals [66, 68, 185]. Other immune cells 
also react to obesity-induced changes in the microenvironment. Eosinophils, which 
normally contribute to the M2 phenotype through the production of IL-4, are displaced by 
infiltrating and M1-promoting neutrophils, mast cells and B cells [186-188]. Overall, the 
immune cells in obese individuals promote an insulin-resistant, pro-inflammatory 
microenvironment. Most importantly, functional depletion of any of these M1-promoting 
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cell populations has been shown to alleviate inflammation and to partially restore insulin 
sensitivity [66, 68, 189]. This implies that therapeutic intervention targeting one of the cell 
populations involved in sustaining the inflammation (e.g., the specific elimination of M1 
macrophages) could prevent the pathology of obesity-induced insulin resistance. 
Macrophages are also key regulators of cancer cells. The tumor promoting 
subpopulation is often referred to as tumor-associated macrophages (TAMs), which 
represent the major link between inflammation and cancer. Tumor-infiltrating Th2 cells 
and the tumor cells themselves produce cytokines (e.g. IL-4, IL-13, IL-10 and/or TGF-β) 
that induce an M2-like phenotype in recruited macrophages. Their presence coincides with 
tumor progression, metastasis, the suppression of adaptive anti-tumor immunity, and often 
poor prognosis [190-196]. The induction of metastatic behavior in tumor cells reflects the 
expression of several enzymes and proteases (e.g. matrix metalloproteinases or plasmin), 
which regulate the digestion of the extracellular matrix [197]. As an alternative to the de 
novo M2 polarization of infiltrating monocytes, a switch from M1 to M2 was identified as 
a progression-related phenomenon in some mouse models of carcinogenesis [198]. In 
contrast to TAMs, M1 macrophages contribute to the T cell-mediated killing of tumor cells 
[199, 200]. Interestingly, in a transplanted mammary carcinoma, TAMs were shown to 
display a mixed phenotype depending on their localization and the signals present within 
the tumor area. Whereas M1 macrophages were dominant in normoxic areas, M2 
macrophages accumulated in hypoxic areas [201]. Therefore, changes in the 
microenvironment can detrimentally influence the spectrum of TAM phenotypes. 
Moreover, TAMs also interact with cancer stem cells. Recently, TAMs were found to 
promote the tumorigenicity of cancer stem cells and drug resistance by releasing milk fat 
globule epidermal growth factor 8 [202]. 
The development of allergy is another complex process that involves different types of 
immune cells including T cells and macrophages. Allergy is associated with Th2 cells and 
M2 macrophages, as well as the corresponding soluble mediators and pathways involved in 
the stimulation of these cell populations [203-205]. Asthma, for instance, is accompanied 
by tissue remodeling, a feature of M2 macrophages. It therefore appears likely that IL-4-
mediated M2 polarization plays a key role in the pathogenesis of these diseases [206]. 
Furthermore, many studies have shown that asthma involves Th2-type cell recruitment and 
cytokines, which affect the airway reactivity and mucus production. Alveolar macrophages 
are resident in the lungs, and they express high levels of CD206, scavenger receptor A, and 
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the β-glycan receptor. In addition, they secrete large amounts of lysozyme and 
immunosuppressive products, thus modulating adaptive immunity in the lungs [45]. In 
contrast to the IL-4/IL-13-driven type 2 inflammation paradigm of allergic reactions, the 
Th1-related cytokines IL-1 and IL-18 have been implicated in allergic reactions [207-209]. 
This illustrates the plasticity among M1/M2 and Th1/Th2 cells, which allows for 
extraordinary fine-tuning of the immune system. 
  
IV.2 Sensitivity of M1 macrophages towards H22(scFv)-delivered proteins 
The aim of this thesis was to develop an M1-targeted therapeutic approach based on ITs, 
taking into account important considerations such as: (1) the selection of a suitable target 
molecule; (2) efficient routing and translocation of the effector molecule to the cytosol; 
and (3) the selection of a potent effector molecule.  
A suitable target molecule was selected by screening polarized macrophages for a set of 
membrane receptors by flow cytometry. The preferential expression of CD64 on M1 
macrophages was confirmed along with other receptors such as CD14, CD25 and CD36. 
However, CD64 has unique features such as its exclusive expression on monocytes and 
macrophages in tissues, although neutrophils also express low levels of CD64 in peripheral 
blood. The number of CD64 molecules on the surface varies from 1 x 104 on monocytes to 
1 x 105 on macrophages [77]. The expression of CD64 on monocytes is not constitutive but 
is induced upon exposure to IFN-γ [210], reflecting the presence of an IFN-γ response 
element within the CD64 promoter [211]. Second, CD64 is thought to sample a constant 
source of extracellular antigens and therefore internalizes bound proteins efficiently, which 
is in turn a prerequisite for the efficacy of ITs [212, 213]. Furthermore, the availability of 
the H22 construct to efficiently target hCD64 on human PBMC-derived macrophages, 
transgenic peritoneal mouse macrophages, and promyelocytic cell lines (HL-60, U937), 
was critical for this project [83-85, 87, 115, 214-216].  
After the internalization of a hCD64-bound IT, the next set of steps involve routing and 
translocation of the effector protein from the endosome to the cytosol. Following uptake, 
the internalized complex undergoes retrograde transport through endosomes to the trans-
site of the Golgi apparatus, which is also the case for ETA'. This process is dependent on 
Rab9, indicating the involvement of late endosomes [217]. The protein complex finally 
reaches the ER using Rab6- and Arf1-dependent pathways as well as the KDEL-mediated 
pathway. The final translocation process can also depend on several factors including the 
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nature of the cytotoxic domain, the design of the fusion protein (e.g., translocation-
supporting peptide sequences between the binding and toxic domains), and the presence of 
a C-terminal ER-retention signal [94-96]. For plant toxins, intracellular transport was 
shown to be regulated by sorting receptors cycling between the ER and the Golgi [96]. The 
cytotoxicity of both plant and bacterial toxins was also shown to be optimal when only the 
toxic domain translocates to the cytosol [218]. The domains are usually separated by 
proteases such as furin, which are predominantly localized in the transreticular Golgi 
[219]. Diphtheria toxin follows an alternative translocation route, in which internalization 
and pH-mediated unfolding in acidified endosomes, is followed by the formation of a 
hairpin that inserts into the membrane of early endosomes and translocates to the cytosol 
[220, 221].  
The final step in the long journey of ITs is the execution of cytotoxicity. The selection 
of a potent effector molecule is based on its ability to induce apoptosis. In this project, the 
catalytically-active ETA' was used as the “gold standard”. However, the selective effect on 
M1 macrophages was not ETA'-dependent. In addition to the human enzymes angiogenin 
and granzyme B, human MAP was able to kill M1 macrophages efficiently when fused to 
H22(scFv). Thus, hCD64 was a suitable target molecule for the specific delivery of a 
cytotoxic payload to M1 macrophages. Although hCD64 was expressed at lower levels by 
M0 and M2 macrophages, the number of hCD64 molecules should nevertheless be 
sufficient to internalize an adequate number of toxin molecules to kill the cells. Therefore, 
the sensitivity of M1 macrophages towards anti-hCD64 ITs must be determined by other 
factors, such as differential routing and processing after internalization. Interestingly, as 
early as in 2000, the sensitivity of IFN-γ activated macrophages was shown to reflect a 
combination of phenotypic changes (e.g. upregulation of hCD64) and changes in the 
overall activation state [85]. Because both the cytotoxic effector protein and cellular target 
were identical in all three macrophage subpopulations, only differential routing could 
explain the differences in cytotoxicity. The endosomal proteolytic activity was therefore 
investigated in the three macrophage subpopulations to assess the potential for differential 
processing. Silica beads were conjugated to ovalbumin coated with the pH-stable 
fluorescent dye DQ Green resulting in fluorescence quenching until the dye is 
proteolytically cleaved from the ovalbumin. This approach was adapted from earlier work 
showing that the activation of macrophages by IFN-γ (M1) reduces the capacity of early 
phagosomes (equal to endosomes) to degrade proteins [222].  
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The reduced protease activity in M1 macrophages and increased activity in M2 
macrophages matches their opposing functions during different phases of the immune 
response. Resident macrophages (presumably M0) degrade cell debris in developing 
tissues, a process described as tissue homeostasis. Upon activation, for example by 
infection, their primary function is to act as an immune effector cell rather than a mere 
phagocyte. The production of pro-inflammatory cytokines, ROI and RNI becomes their 
main task [39]. However, phagocytosis and the degradation of pathogens may not be shut 
down completely but may instead be shifted to an apparently more controlled degradation 
process, thus ensuring the presentation of the complete epitope repertoire to T cells. This is 
also supported by the increased expression of both MHC molecules on M1 macrophages 
which confirms the importance of these cells for antigen presentation. In contrast to the 
MHCII-rich pre-lysosomal compartments, where epitopes are captured and loaded onto 
MHC molecules, the ability of late phagolysosomes in M1 macrophages to degrade 
proteins is not reduced [223, 224]. This is a logical response allowing the destruction of 
intracellular pathogens, and emphasizes the bivalent activity of M1 macrophages, which 
fulfill both homeostatic and activation-dependent tasks.  
M2 macrophages were found to possess greater protease activity than resting M0 cells, 
which matches their function in tissue remodeling and repair. Indeed, acidic proteases such 
as cathepsin B and cathepsin D may play a role in antigen processing in the context of 
MHCII presentation [225]. The results of this doctoral thesis confirmed that the inhibition 
of certain acidic proteases, including cathepsin B, causes previously-resistant M2 
macrophages to become sensitive towards H22(scFv)-ETA', correlating with the reduced 
endosomal protease activity. It remains to be determined whether the lower endosomal 
protease activity in M1 macrophages could result in the presentation of epitopes derived 
from the IT to T cells. If so, the subsequent production of neutralizing antibodies would 
reduce or even totally abolish the therapeutic effect of the IT and make a repetitive 
administration impossible. However, the escape and translocation of even a single effector 
protein to the cytosol is sufficient to induce apoptosis. Moreover, this work describes a 
new fully human cytolytic fusion protein (H22(scFv)-MAP) which would circumvent the 
above problem due to the potential absence of immunogenicity.  
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IV.3 Human CFPs as new therapeutic entities 
One prominent goal in passive immunotherapy is the targeted delivery of highly cytotoxic 
payloads to malignant cells. This can be achieved using bifunctional molecules, 
comprising a targeting component and a cytotoxic component. The targeting component 
can be a full-size mAb, a fragment thereof, or a protein ligand (e.g. a growth factor or 
cytokine) [89-92]. A variety of reagents have been used as cytotoxic components, 
including radioisotopes, small-molecule drugs and protein-based toxins derived from 
bacteria or plants. Depending on the linkage between the targeting and cytotoxic 
components, these molecules are described as antibody drug conjugates (ADCs) with 
chemical cross-linking between synthetic cytotoxic molecules and antibodies, or ITs if 
cytotoxic proteins are genetically fused to the targeting protein [226-229]. Both ADCs and 
ITs can overcome the disadvantages of naked mAbs, which often require a functional host 
immune system for their therapeutic effect [230-234].  
At least 22 ADCs are currently undergoing clinical trials, and brentuximab vedotin, for 
example, has already been approved by the FDA for the treatment of anaplastic large cell 
and Hodgkin lymphoma [235-237]. Interestingly, the cytotoxic domain of brentuximab 
vedotin is monomethyl auristatin E, a synthetic analog of the tubulin polymerization 
inhibitor dolastatin 10 [238]. The success of this ADC underlines the enormous potential of 
cytostatic agents delivered by targeted immunotherapy. Despite their promising 
performance in clinical trials, the non-directed chemical linkage of the cytotoxic compound 
in ADCs results in an undefined stoichiometry and heterogenic positioning of the cytotoxic 
payload in relation to the binding protein, which can directly affect its therapeutic efficacy 
[239]. Most ADCs currently undergoing clinical evaluation contain small synthetic 
cytotoxic molecules, such as maytansinoids or taxanes [235]. Similarly, one disadvantage 
of chimeric ITs is their combination of a human or humanized binding component (e.g. a 
single-chain antibody fragment, scFv) and a toxin derived from bacteria or plants, which 
can induce undesirable immune responses and dose limitations e.g. due to vascular leak 
syndrome [105, 110]. For instance, based on numerous clinical trials, the incidence of 
immunogenicity after a single dose of IT ranges from 50–100% for solid tumors, and 0–
40% for hematological tumors. However, the induction of an immune response does not 
always generate neutralizing antibodies, and patients have responded to IT treatment after 
immunogenicity has been documented [105, 240].  
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These shortcomings have been addressed by using pro-apoptotic human enzymes in the 
context of fully human CFPs. Human RNases 1, 2, 3 and 5 (angiogenin), which degrade 
RNA and induce apoptosis by inhibiting protein synthesis, have been used to replace non-
human toxins [241]. The specific cytotoxicity of human angiogenin towards CD30-
overexpressing Hodgkin lymphoma-derived cell lines has been demonstrated by fusion with 
the CD30 ligand, CD30L [127]. Another CD30-targeted CFP was shown to kill CD30-
overexpressing tumor cells efficiently when combined with human death-associated 
protein kinase 2 [242]. In 2008, a completely human granzyme B-based CFP directed 
against CD64 was found to be toxic towards an acute myeloid leukemia (AML)-related 
cell line and primary AML cells [115]. Thus far, various human proteins including RNases, 
perforin, Bik, Bak, Bax, DNA fragmentation factor 40, FAS ligand and TNF-related 
apoptosis-inducing ligand have been used as toxic effector molecules [243].  
Although most of the above mentioned effectors have been tested for toxicity towards 
cancer cells, they could potentially be applied in other indication areas such as autoimmune 
and chronic inflammatory disorders. This has been successfully demonstrated in this thesis 
by targeting pro-inflammatory M1 macrophages with a new CFP: H22(scFv)-MAP. 
Interestingly, the killing of M1 macrophages in vivo by H22(scFv)-MAP, which is 
cytotoxic only to proliferating cells, suggested that the proliferation of mononuclear cells is 
not limited to circulating monocytes, but also affects differentiated tissue macrophages. In 
addition to this indirect proof, the proliferation of M1 macrophages was also confirmed 
directly in mouse skin by the detection of CD64+Ki67+ M1 cells, supporting recently 
published data indicating that macrophages proliferate in situ rather than being replenished 
from the circulation [244].  
Despite the significance of these novel physiological properties of tissue macrophages, 
the proliferation-dependent mode of action of MAP-based CFPs will have a significant 
impact on the treatment of cancer. The intrinsic property of cancer cells to divide 
constitutively makes them a suitable target for this new effector protein. Since the modular 
architecture of CFPs allows the binding component to be replaced quickly by genetic 
engineering, new binding ligands, antibodies or fragments thereof could be used to 
specifically target cancer cells. MAP provides a sophisticated approach for the treatment of 
cancer, combining selectivity for target cells mediated by the binding component and the 
cytotoxic payload.  
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Generally, only the binding domain of CFPs confers selectivity and specificity, whereas 
the cytotoxic component is chosen according to its ability to induce apoptosis or inhibit 
protein synthesis. However, most tumor markers are also expressed on physiologically-
normal cells resulting in undesirable off-target effects. Cytostatic agents such as taxanes 
(e.g. paclitaxel) have superior selectivity. Taxanes are microtubule-stabilizing agents and 
are currently used in a wide range of indications including cancer (e.g. breast cancer, 
ovarian cancer, non-small cell lung carcinoma) and hematological malignancies [245-247]. 
Taxanes conjugated to mAbs have also been tested successfully for the treatment of 
tumors. The mode of action is based on binding to and stabilizing polymerized microtubule 
filaments, resulting in a change in the total microtubule mass (if high concentrations of the 
stabilizing agent are present) or microtubule dynamics. Both changes lead to cell cycle 
arrest and the induction of apoptosis [248-250].  
Taxanes can be chemically conjugated to the targeting component using state-of-the-art 
chemistry. In contrast, microtubule-associated proteins such as MAP, survivin, stathmin, 
dynactin-1 and MCAK, could be used as fusion proteins [117-121]. In physiologically-
healthy cells, microtubule-associated proteins orchestrate the fine-tuning of microtubule 
dynamics, thus allowing the polymers to fulfill diverse functions. In resting cells 
(interphase), microtubules are replaced slowly, with half-lives of minutes to hours, whereas 
microtubule disassembly and polymerization from spindle microtubules occurs up to 100-
fold more rapidly during mitosis, and this increased rate is crucial for successful cell 
division [123, 124]. The dynamics of microtubule assembly and disassembly is tightly 
controlled by microtubule-associated proteins, which are themselves regulated by 
phosphorylation [125]. Therefore, the presence of non-phosphorylated MAP during mitosis 
(achieved by removing critical phosphorylation sites) was predicted to reduce the 
dynamics to a critical degree and to induce apoptosis. This hypothesis was confirmed by 
testing several MAP-based CFPs each targeting a different tumor marker. EGF-MAP was 
able to selectively kill EGFR+ cancer cells in a proliferation-dependent fashion by inducing 
apoptosis. In vitro results confirmed high selectivity, specificity and efficacy against 
L3.6pl cells. Optical imaging also confirmed that EGF-MAP suppressed tumor growth in 
vivo (manuscript to be submitted). Similar results were achieved using anti-EpCAM(scFv)-
MAP (manuscript to be submitted), Ki4(scFv)-MAP (manuscript in preparation), and 
scFv35-MAP (manuscript in preparation). 
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The safety and immunogenicity of MAP was evaluated by attempting to determine the 
maximum tolerated dose (MTD) in a dose escalation study. Compared to the MTD of 
425(scFv)-ETA' (1.0 mg/kg) [251], a dose of 4.0 mg/kg of EGF-MAP could be 
administered without adverse effects and an MTD was not reached during testing. Cancer 
immunotherapy using protein-based therapeutics such as EGF-MAP will require repetitive 
administration, thus the promising safety profile and the apparently low immunogenicity of 
CFPs make them superior to classical ITs.  
Because ‘tau’ is also the name of a protein associated with Alzheimer’s disease, it is 
important to emphasize that the MAP tau protein described herein is not able to form the 
pathologically relevant paired helical filaments and our proposed therapeutic strategy does 
not increase the risk of neurodegenerative disorders [252-255].  
The cytotoxic efficacy of human effector proteins is not yet comparable to that of 
bacterial ETA. The higher IC50 values observed for MAP-based CFPs in vitro also reflect 
its lack of enzymatic activity (ETA is an ADP-ribosyl transferase that acts catalytically 
against its targets, whereas MAP binds stoichiometrically to microtubules). However, the 
cytotoxic activity of CFPs such as MAP could be improved by the insertion of an adapter 
sequence, which facilitates translocation of the effector molecule from the endosome to the 
cytosol [94, 256]. For example, it has been reported that only 3–4% of internalized ETA is 
ultimately translocated to the cytosol [257]. Improving the translocation efficiency could 
therefore significantly enhance the therapeutic potential of CFPs to make them even more 
suitable for clinical applications. The proliferation-dependent mode of action means that 
MAP-based CFPs could also be used to target cancer stem cells. In contrast to the 
stochastic model, the cancer stem cell model has been proposed as an explanation for 
tumor propagation, based on the presence of stem-cell like tumor cells with a higher 
capacity to proliferate and differentiate [258].  
 
IV.4 Potential scope of M1-targeting therapies 
Polarized macrophages play a critical role in many immunological diseases. It is not the 
polarization state itself that leads to pathogenicity but rather its inappropriate duration and 
persistence during the course of inflammation [259, 260]. An overview of the role of 
polarized macrophages in health and disease is provided above (IV.1). In this chapter, the 
focus will be set to M1 macrophages and their contribution to the pathology of diverse 
diseases. The central finding of this thesis was that M1-specific killing using hCD64-
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targeted ITs provides a novel therapeutic approach for the treatment of M1-associated 
diseases. On the whole, such diseases can be divided into two etiological groups: In the 
first group, the inflammatory response is triggered by an exuberant, pathological 
autoimmune cascade, which causes diseases such as RA, arthritis, SLE, psoriasis and MS 
[15, 52, 53, 261]. In the second group, chronic inflammation is associated with age and is 
the basis of most cardiovascular diseases (e.g. atherosclerosis), obesity-associated insulin 
resistance (e.g. diabetes type 2), and almost all neurodegenerative diseases (e.g. 
Alzheimer’s disease) [262]. On the cellular level, diseases of both etiologies have been 
associated with the persistence of M1 macrophages leading to non-resolving inflammation 
and tissue damage. Increased understanding of the molecular pathology of these diseases 
led to the development of diverse anti-inflammatory therapeutic strategies, but this requires 
the identification of appropriate targets allowing the arrest or even the prevention of 
inflammation. Recently, Tabas and Glass reviewed current treatment options and future 
opportunities in chronic diseases, emphasizing that the involvement of many signaling and 
effector molecules in inflammation makes therapies focusing on one or few of these 
molecules ineffective. This often reflects the compensation of one blocked component by 
an alternative one via feedback pathways. Another critical factor is that the systematic 
inhibition of acute inflammation weakens host defense and compromises immunity [262].  
Treatment options for chronic diseases triggered by pathological autoimmune cascades 
fall into three therapeutic categories: non-steroidal anti-inflammatory drugs (NSAIDs), 
glucocorticoids, and disease-modifying agents for rheumatoid diseases (DMARDs) [263]. 
Whereas the first two classes merely contribute to symptomatic relief, DMARDs are 
genetically engineered recombinant proteins that reduce or prevent tissue damage caused 
by uncontrolled inflammation. This class of therapeutics includes non-biological reagents 
such as low-dose methotrexate, which inhibits the inflammatory potency of certain 
immune cells, and biological reagents such as mAbs that block specific receptors (e.g. 
IL-1R) or soluble mediators (e.g. TNF-α or IL-1β) [262]. Statins can also reduce 
inflammation in MS, RA and SLE [264]. 
In contrast to chronic inflammatory diseases associated with autoimmunity, age-
associated chronic inflammation can be triggered by diverse signals including excess 
subendothelial apolipoprotein B-containing lipoproteins, saturated fatty acids or protein 
aggregates. These molecules form so-called disease-specific damage-associated molecular 
patterns (DAMPs), which are recognized by immune cells via pattern recognition 
Discussion 
78 
 
receptors. Subsequent induction of inflammation enhances the production of e.g. oxidized 
phospholipids, which act as important DAMPs in atherosclerosis and promote the 
formation of β-amyloid aggregates in Alzheimer’s disease [265, 266]. Current therapeutic 
approaches for diseases in this etiological group include statins, which have potent anti-
inflammatory properties by interfering with the isoprenoid biosynthesis [264, 267]. Most 
studies have focused on the cardioprotective and insulin-sensitizing effects of statins, 
which make them interesting candidates for the treatment of atherosclerosis and type 2 
diabetes [268, 269]. Interestingly, certain statins (e.g., pravastatin® and rusovastatin®) can 
improve insulin resistance irrespective of decreasing obesity in obese subjects with and 
without diabetes, while other statins (e.g., simvastatin®) cannot, even though a comparable 
improvement in the levels of inflammatory markers was observed [270-273]. Alternative 
therapeutic strategies for cardiovascular and metabolic disorders include neutralizing 
mAbs that target TNF-α (e.g. etanercept® or infliximab®) or synthetic agonists that target 
peroxisome proliferator-activated receptors (PPARs)-γ and -δ [262, 274, 275].  
In total, increasing understanding into the complex communication among different 
immune cells and the microenvironment has promoted interest in the development of 
targeted therapies for chronic inflammatory diseases using biological and non-biological 
reagents. Despite encouraging advances, all current approaches suffer unequivocal 
limitations as illustrated by the following examples: Although the systemic inhibition of 
TNF-α prevents the secretion of many other pro-inflammatory cytokines in addition to 
TNF-α itself, the impact of anti-TNF-α therapy was disappointing in patients with diabetes, 
psoriasis and RA [261, 276]. Even worse, it appears to be harmful when used for the 
treatment of MS [277]. Based on the pathological role of M1 macrophages and the healing 
promoting role of M2 macrophages, one may hypothesize that the neutralization of pro-
inflammatory signals produced by M1 cells may not be sufficient to restore the 
physiological conditions present during M2 dominance. The M1-targeting therapies 
discussed in this thesis could address this challenge by specifically killing M1 
macrophages, interrupting all downstream inflammatory processes and therefore 
promoting an M2-dominant milieu to resolve inflammation. In the context of the risk-to-
benefit question addressed by Tabas and Glass [262], the CD64-mediated elimination of 
M1 macrophages ensures local depletion, focusing only on differentiated tissue M1 
macrophages thus allowing, in response to infections for example, new infiltrating 
macrophages to be primed and polarized towards M1 cells as necessary to confer host 
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defense. Interestingly, and in contrast to anti-TNF-α therapy, there is evidence for a direct 
relationship between the mode of action of statins and PPAR-γ/δ agonists and the 
promotion of M2 polarization in tissue macrophages [278]. This underlines the importance 
of macrophage plasticity and presents a completely different approach to re-balance the 
M1/M2 ratio.  
As well as the specific elimination of M1 macrophages, this thesis also shows that M1 
macrophages can be re-polarized into M2 macrophages using IL-4 as a stimulus, a form of 
immunomodulation. Successful immunomodulation of macrophages has already been 
demonstrated in the context of atherosclerosis using the oxidative-stress limiting protein 
thioredoxin-1 to promote M2-like macrophage polarization, reducing the area of aortic 
lesions in an in vivo atherosclerosis model [279]. Another example is the phospholipid 
transfer protein (PLTP). In vitro studies with differentiated THP1 cells and human 
monocyte-derived macrophages revealed that PLTP can reduce the nuclear levels of active 
NFκ-B p65 and the secretion of pro-inflammatory cytokines [280]. 
Although the proteins described above show encouraging immunomodulatory activities, 
they are all untargeted. The immunomodulation of M1 macrophages using a soluble 
cytokine such as IL-4 will therefore not be feasible in vivo, due to unpredictable systemic 
effects. Nonetheless, the lesson learned from these proteins is that interfering with signal 
transduction pathways responsible for M1 polarization (e.g. the activation of NF-κB or 
STAT1) may offer a promising immunomodulation strategy. In that respect, CD64 offers 
suitable access to M1 macrophages and in combination with the reduced degradation of 
internalized proteins in the endosomes, hCD64-targeted immunomodulatory fusion 
proteins could be promising candidates for the targeted treatment of chronic inflammatory 
diseases in the future.  
 
IV.5 Outlook 
The work described in this thesis demonstrates the M1-specific elimination of polarized 
macrophages using hCD64-targeted therapeutic proteins. In addition to the chimeric 
immunotoxin H22(scFv)-ETA', two fully human CFPs, H22(scFv)-Angiogenin and 
Granzyme B-H22(scFv), were also able to eliminate M1 macrophages. Furthermore, a 
novel human effector protein (MAP) was able to induce apoptosis in proliferating target 
cells. Successful killing of M1 macrophages by H22(scFv)-MAP in vivo further revealed 
the capability of fully-differentiated tissue macrophages to proliferate in situ. Importantly, 
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M1-specific elimination was confirmed both in vitro and in a hCD64tg SLS-induced 
chronic cutaneous inflammation mouse model in vivo. The same results were obtained with 
a human skin biopsy derived from a patient with atopic dermatitis, thus highlighting the 
potential clinical relevance of M1-targeted immunotherapy. More human skin biopsies 
should be analyzed in the future to confirm that the elimination of M1 macrophages can 
resolve chronic inflammation. Biopsies from patients with different chronic inflammatory 
diseases (e.g. diabetic ulcer, arthritis, etc.) will broaden the potential range of indications 
for this therapy. 
Additional future investigations should focus on the identification of 
immunomodulatory proteins affecting macrophage polarization. Candidates must fulfill 
two major prerequisites for M1-targeted therapy. First, they should interfere with the 
pathways involved in M1 polarization. Although the STAT1 and NF-κB are appropriate 
targets, it would be interesting to explore the immunomodulation of macrophage 
polarization at the epigenetic level by targeting recently-identified epigenetic mediators of 
M1 polarization such as Imjd3 (a JmjC family histone demethylase) and histone 
deacytelase 3 (HDAC3) [281-283]. Targeting these enzymes with specific inhibitors would 
provide an elegant alternative immunomodulatory approach. Second, these proteins must 
be suitable for genetic fusion with hCD64-targeting ligands or antibodies. Ideally, 
immunomodulation should inhibit the production of critical soluble mediators (e.g. IL-12 
or IL-6, and induce the production of M2-associated molecules (e.g. IL-10).  
Depending on the indication, the optimal administration route for the cytotoxic or 
immunomodulatory fusion protein must be determined. In this study, mice received 
intradermal injections, which ensured the local targeting of M1 macrophages. However, in 
other chronic inflammatory diseases (e.g. MS or RA), different administration routes might 
be necessary, e.g. intravenous, intramuscular or intraperitoneal. In the case of chronic 
wounds, topical application in the form of a wound dressing, cream or protein-modified 
patches might be the most appropriate strategy. 
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V Summary 
 
Macrophages represent an essential part of the innate immune system and are credited with 
a crucial role in regulation of inflammation, host defense, tissue remodeling and 
homeostasis. Diversity and plasticity are hallmarks of this cell lineage, and in response to 
stimuli such as IFN-γ or IL-4, they undergo polarization towards M1 or M2 macrophages. 
These subpopulations mirror two extremes of a continuum and are the best studied 
subtypes of polarized macrophages. Since both M1 and M2 macrophages are responsible 
for the correct progress of diverse physiological processes, a disrupted M1/M2 balance is 
often pathological. This has been confirmed in many chronic inflammatory and 
autoimmune diseases. Under physiologically-normal conditions, M1 macrophages 
predominate in the early phases of inflammation, mediating clearance and orchestrating the 
recruitment of other effector cells. In contrast, M2 macrophages predominate at the end of 
inflammation, promoting vascularization and new tissue formation. In chronic 
inflammation, M1 macrophages fail to switch to M2, leading to the reinforcement of a pro-
inflammatory environment and the persistence of the M1 dominant phase, leading to 
chronicity and tissue damage. There are currently no targeted therapeutic strategies 
focusing on macrophages for the treatment of chronic disorders. 
In this thesis, the lack of available strategies for the treatment of chronic inflammatory 
diseases was addressed using hCD64-targeted immunotoxins (ITs). Murine and human 
macrophages were polarized and characterized using a set of membrane and soluble 
markers. Among several other surface receptors including CD14, CD16 and MHCI/II, 
CD64 was unique due its increased expression in both murine and human M1 cells. M1 
macrophages were also characterized by the increased production of pro-inflammatory 
cytokines such as IL-12, IL-6 and TNF-α. In contrast, CD206 and CD301 were more 
abundant on the surface of M2 macrophages and the pro-inflammatory cytokines listed 
above were suppressed. Although non-polarized (M0) and M2 macrophages expressed 
CD64 on their surface, subsequent in vitro targeting experiments revealed the exclusive 
elimination of M1 type macrophages by three different hCD64-targeted proteins: the 
chimeric IT H22(sFv)-ETA' and the two fully human fusion proteins H22(scFv)-
Angiogenin and Granzyme B-H22(scFv). Staining with AnnexinV-FITC confirmed that 
H22(scFv)-ETA' selectively induced apoptosis in M1 macrophages. To unravel the basis of 
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this selectivity, the endosomal protease activity of polarized macrophages was investigated 
using fluorescent silica beads. Whereas the endosomal protease activity of M2 
macrophages was elevated compared to M0 cells, it was significantly decreased in M1 
cells indicating that proteins internalized by M1 (but not M2) macrophages avoid 
endosomal degradation and can successfully translocate to the cytosol to realize their 
cytotoxic potential. Both populations could be re-polarized with opposing stimuli, but after 
conversion only M1 polarization resulted in sensitivity to H22(scFv)-ETA'. Finally, M1-
specific elimination of polarized macrophages was confirmed in vivo in a SLS-induced 
cutaneous chronic inflammation model in transgenic mice and ex vivo in a human skin 
biopsy from a patient with atopic dermatitis underlining the clinical relevance of an M1-
targeted therapy. Most importantly, the pinpoint elimination of M1 macrophages induced 
the conversion of resident macrophages to the M2 phenotype. 
In an attempt to replace the immunogenic bacterial toxin ETA' with a fully human 
effector protein, the ability of the human microtubule-associated protein tau (MAP) to act 
as a pro-apoptotic protein was investigated. Therefore, MAP was cloned in frame with 
H22(scFv), expressed in E. coli, and purified by standard chromatographic methods. 
Successful binding of H22(scFv)-MAP to the promyelocytic leukemia cell lines HL-60 and 
U937, and to polarized macrophages, was confirmed by flow cytometry. In vitro cell 
viability assays revealed the proliferation-dependent cytotoxicity of H22(scFv)-MAP. The 
in vivo performance was tested in the transgenic mouse model described above, revealing 
that H22(scFv)-MAP also selectively eliminated M1 macrophages, while leaving M2 
macrophages unaffected. The successful killing of M1 macrophages by H22(scFv)-MAP, 
which confers cytotoxicity to proliferating cells only, suggested that fully differentiated 
and polarized tissue macrophages proliferate in situ. The local proliferation of M1 
macrophages was confirmed by immunohistochemical analysis. 
In summary, these results show that CD64 is an appropriate target for therapeutic 
approaches focusing on M1 macrophages and attempting to alter their function or role in 
chronic inflammation. Specific targeting of M1 macrophages provides a therapeutic 
strategy to intervene in most chronic inflammatory diseases, e.g. rheumatoid arthritis, 
inflammatory bowel disease and chronic wounds.  
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VII.2 Abbreviations 
Ab      antibody 
Ag      antigen 
AML     acute myeloid leukemia 
Ang     angiogenin 
AP      alkaline phosphatase 
APS     ammonium persulfate 
Arg     arginase 
ATCC     American Type Culture Collection 
b.d.     below detection limit 
bp      base pair 
BSA      bovine serum albumin 
CCP     cytosolic cleavable peptide 
CD     cluster of differentiation 
CSF     colony stimulating factor 
dH2O     deionized water 
DMF     dimethylformamide 
DNA      deoxyribonucleic acid 
dNTP      deoxynucleotide triphosphate 
DSMZ     Deutsche Stammsammlung von Mikroorganismen  
                                                           und Zellkulturen 
DT     diphtheria toxin 
DTT      dithiothreitol 
ECP     endosomal cleavable peptide     
EDTA     ethylenediaminetetraacetic acid 
EF      eukaryotic elongation factor 
EGF     epidermal growth factor 
EK     enterokinase 
ELISA     enzyme linked immunosorbent assay 
ER     endoplasmic reticulum 
ETA'      Pseudomonas exotoxin A, deletion mutant 
Fab     fragment antigen binding 
FACS      fluorescence-activated cell sorting 
FC     flow cytometry 
FcγR     Fcγ receptor 
FCS     fetal calf serum 
FITC      fluorescein isothiocyanate  
x g      relative centrifuge force 
Gb     granzyme B 
hCD64    human CD64 
hCD64tg    transgenic for human CD64 
CFP     cytolytic fusion protein 
His-tag     polyhistidine motif 
HO-1     heme oxygenase-1 
HRP      horseradish peroxidase 
IBD     inflammatory bowel disease 
IC50      inhibitory concentration at 50% survival 
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IF     immunofluorescence 
IFN-γ     interferon-γ 
IgG      immunoglobulin G 
IHC     immunohistochemistry 
IL     interleukin 
IMAC      immobilized metal ion affinity chromatography 
iNOS     inducible nitric oxide synthase 
IPTG      isopropyl-beta-D-thiogalactopyranoside 
IT      immunotoxin 
Kan      kanamycin 
kb      kilobase 
kDa      kiloDalton 
LB      luria broth 
mAb     monoclonal antibody 
MAP     microtubule-associated protein 
MΦ     macrophage(s) 
MFI     mean fluorescence intensity 
MHC      major histocompatibility complex 
MTP     membrane transfer peptide 
MS     multiple sclerosis 
NBT-BCIP    nitro blue tetrazolium chloride/5-bromo-4-chloro-3-   
                                                           indolyl phosphate 
NK     natural killer cell(s) 
NLS     nuclear localization sequence 
NTA      nitrilotriacetic acid 
OD      optical density 
ORF     open reading frame 
ori      origin of replication 
PAGE      polyacrylamide gel electrophoresis 
PBMCs    peripheral blood mononuclear cells 
PBS      phosphate buffered saline 
PBST      phosphate buffered saline + 0.05% Tween 20 
PCR      polymerase chain reaction 
pH     negative logarithm of the concentration of hydrogen  
                                                           ions in solution 
PI      propidium iodide 
PMA     phorbol 12-myristate 13-acetate 
PTX3     pentraxin 3 
RA     rheumatoid arthritis 
RELM -α    resistin-like molecule α 
RNA     ribonucleic acid 
RNI     reactive nitrogen intermediates 
ROI     reactive oxygen intermediates 
(R)PE     (R-)phycoerythrin 
rpm      rotations per minute 
scFv      single chain fragment variable 
SD     standard deviation 
SD-1     sulfiredoxin-1      
SDS      sodium dodecyl sulfate 
SEC      size exclusion chromatography 
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SEM     standard error of mean 
SLAM     signaling lymphocytic activation molecule 
SLE     systemus lupus erythematosus 
SLS     sodium lauryl sulfate (=SDS) 
TAE      trisacetate EDTA buffer 
TEMED    tetramethylethylenediamine 
TGF-β     tumor growth factor-β 
Th     T helper cell(s) 
TLR     Toll-like receptor 
TNF     tumor necrosis factor 
TR-reductase    thioredoxin-reductase      
Tris      tris(hydroxymethyl)aminomethane 
Tween 20     polyoxyethylene (20) sorbitan monolaurate 
U      unit(s) 
UV      ultraviolet 
v/v      volume per volume 
VEGF     vascular endothelial growth factor 
w/v      weight per volume 
WB     western blotting 
XTT      sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium] 
                                                           -bis(4-methoxy-6-nitro)benzenesulfonic acid hydrate 
YM1     heparin binding lectin 
 
VII.3 Sequences 
Nucleotide and amino acid sequences of pMT-H22(scFv)-MAP are shown below. 
Abbreviations: MBR1-4, microtubule binding repeat 1-4; NLS, nuclear localization 
sequence; EK, enterokinase; MAP, microtubule-associated protein tau-3. Point mutations 
for removal of phosphorylation sites are indicated by short red arrows (S156A and S204A). 
Relevant restriction sites are shown. 
 
 
Appendices 
107 
 
 
 
 
Appendices 
108 
 
 
 
 
 
Appendices 
109 
 
 
 
 
 
Appendices 
110 
 
 
 
 
 
Appendices 
111 
 
 
 
 
 - 112 - 
 
Acknowledgements 
 
First of all, I would like to express my greatest thanks to my doctoral advisor Prof. Dr. 
Rainer Fischer for supervising this thesis and for supporting me throughout my academic 
education. Thank you for giving the right directions and for trusting in me! 
 
I would like to thank Prof. Dr. Dr. Stefan Barth for giving me the chance to work in his 
department, for co-supervising me, and for giving me working freedom during the last 
years. 
 
I wish also to thank Prof. Dr. Andreas Ludwig for again agreeing to act as co-referent.  
 
I am indebted to Dr. Theo Thepen for allowing me to work in his group, for practically 
supervising this project, and for critically reading this thesis. Also, thank you Theo for 
taking time to answer my questions and for giving valuable advices. 
 
My special thanks go to my friend and colleague Radoslav Mladenov. Thank you Rado 
for helping me with experiments, for fixing frequently occurring computer errors, and for a 
great time in and outside the lab! I wish you all the best for your future scientific carrier! 
 
For their kind help in the lab, I am very grateful to Reinhard, Anh-Tuan, Severin, and 
Kai. 
 
I would like to thank Dr. Richard Twyman for critically reading this thesis. 
 
Finally, I would like to say thank you to my parents, my girlfriend Katja and her 
parents for always encouraging and supporting me. 
 
 113 
 
Scientific Publications 
 
Patents 
Hristodorov, D., Mladenov, R., Thepen, T., and Barth, S. (2012) Human microtubule-
associated cytotoxic protein fusions for the treatment of proliferating diseases. European 
Patent EP12186382. 
 
Hristodorov, D., Mladenov, R., Barth, S., and Thepen, T. (2013) Targeted modulation of 
macrophages. European Patent EP13169381. 
 
Publications 
Hristodorov, D., Mladenov, R., Huhn, M., Barth, S., and Thepen, T. (2012) Macrophage-
targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory 
diseases. Toxins 4(9) 676-694. 
 
Schiffer, S*., Hristodorov, D*., Mladenov, R., Aslanian, E., Huhn, M., Fischer, R., Barth, 
S., and Thepen, T. (2013) Species-dependent functionality of the human cytolytic fusion 
proteins Granzyme B-H22(scFv) and H22(scFv)-Angiogenin in macrophages. Antibodies  
2(1) 9-18. * authors contributed equally to this work 
 
Hristodorov, D., Mladenov, R., Aslanian, E., Huhn, M., Barth, S., and Thepen, T. (2012) 
Macrophage-targeted therapy of chronic wounds. Book chapter in: Chronic Inflammation: 
Causes, Treatment Options and Role in Disease (in press). 
 
Hristodorov, D., Fischer, R., Joerissen, H., Muller-Tiemann, B., Apeler, H., and Linden, 
L. (2013) Generation and Comparative Characterization of Glycosylated and 
Aglycosylated Human IgG1 Antibodies. Molecular Biotechnology 53(3) 326-35. 
 
Hristodorov, D., Fischer, R., and Linden, L. (2012) With or without sugar? - 
(A)glycosylation of therapeutic antibodies. Molecular Biotechnology 54(3) 1056-68. 
 
 
 
 114 
 
Hristodorov, D., Mladenov, R., Pardo, A., Pham, A.T., Huhn, M., Fischer, R., Thepen, T., 
and Barth, S. (2013) Microtubule-associated protein tau facilitates the targeted killing of 
proliferating cancer cells in vitro and in a xenograft mouse tumor model in vivo. British 
Journal of Cancer. (accepted) 
 
Hristodorov, D., Mladenov, R., von Felbert, V., Huhn, M., Fischer, R., Barth, S., and 
Thepen, T. (2013) Targeting human CD64 mediates selective elimination of M1 but not 
M2 polarized macrophages in chronic inflammation. (submitted) 
 
Hristodorov, D., Mladenov, R., Huhn, M., Fischer, R., Barth, S., and Thepen, T. (2013) 
Fully-human H22(scFv)-MAP eliminates CD64+ leukemia HL-60 cells in vitro and pro-
inflammatory M1 macrophages in a transgenic mouse model in vivo. (to be submitted)  
 
Hristodorov, D., Mladenov, R., Amoury, M., Huhn, M., Helfrich, W., Fischer, R., 
Thepen, T., and Barth, S. (2013) Targeting EpCAM-overexpressing carcinoma cells with a 
novel human fusion protein. (to be submitted) 
 
Hristodorov, D., Nordlohne, J., Mladenov, R., Huhn, M., Fischer, R., Thepen, T., and 
Barth, S. (2013) Human microtubule-associated protein tau mediates targeted killing of 
CD30+ Hodgkin lymphoma cells in vitro and in vivo. (manuscript in preparation) 
 
Hristodorov, D., Mladenov, R., Fischer, R., Barth, S. and Thepen, T. (2013) Pre-Blocking 
CD64 with H22(scFv) as possible strategy to augment the effect of anti-TNF-α therapy. 
(manuscript in preparation) 
 
Schiffer, S., Letzian, S., Hehmann-Titt, G., Jost, E., Mladenov, R., Hristodorov, D., Huhn, 
M., Fischer, R., Barth, S., and Thepen, T. (2013) Granzyme M as a novel effector molecule 
for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against 
leukemic cells. Cancer Letters (accepted). 
 
 
 
 
 115 
 
Poster presentations 
Hristodorov, D., Mladenov, R., von Felbert, V., Huhn, M., Fischer, R., Barth, S., and 
Thepen, T. (2013) Fighting chronic inflammation – CD64-specific elimination of M1 
macrophages. Biomedica, Aachen, Germany (Poster Award Winner). 
  
Hristodorov, D., Mladenov, R., Pardo, A., Pham, A.T., Huhn, M., Fischer, R., Thepen, T., 
and Barth, S. (2013) Novel human fusion protein kills proliferating cancer cells.              
Biomedica, Aachen, Germany. 
 
Hristodorov, D., Mladenov, R., von Felbert, V., Huhn, M., Fischer, R., Barth, S., and 
Thepen, T. (2013) Fighting chronic inflammation – CD64-specific elimination of M1 
macrophages. 15th International Congress of Immunology, Milano, Italy. (abstract 
published in Frontiers in Immunology) 
 
Hristodorov, D., Mladenov, R., von Felbert, V., Huhn, M., Fischer, R., Barth, S., and 
Thepen, T. (2013) Fighting chronic inflammation – CD64-specific elimination of M1 
macrophages. Annual Meeting of the German Immunology Society, Mainz, Germany. 
 
 
 
 
 116 
 
Curriculum Vitae 
 
 
 Personal details 
  
Name:  Dmitrij Hristodorov 
Date of birth: 04th May 1986   
Place of birth:                                  Krasnokutsk (Kasachstan) 
Citizenship:                                      German 
 
 
 School Career 
 
09/1992 – 05/1997                          Primary- and High School of Krasnokutsk 
08/1997 – 06/1998                          Secondary Modern School of Juelich (Hauptschule) 
08/1998 – 06/2005                          Grammar School of Juelich (Gymnasium Zitadelle) 
  Degree: Abitur (Grade: 1.4) 
 
 
 Professional Career 
 
05/2013 – 12/2013                           Post-Doc at Fraunhofer IME, Aachen 
 
5/2011 – 5/2013                               PhD Thesis (Dr. rer. nat.) at Fraunhofer IME, Aachen 
                                                         Title: “CD64-Mediated Specific Elimination of M1-    
                                                         Polarized Macrophages - Implications For Therapeutic  
                                                         Intervention in Chronic Inflammatory Diseases” 
                                                         (Grade: summa cum laude) 
 
10/2009 – 04/2011                           Master of Science in Molecular Biotechnology at the  
                                                         University of Aachen; Graduation with Honors      
                                                         (Grade: 1.1) 
 
 
 117 
 
10/2010 – 04/2011                           Master Thesis at Bayer HealthCare in Wuppertal 
                                                         Title: „Generation and Characterization of   
                                                         Glycosylated and Aglycosylated Antibody Drug   
                                                         Conjugates” (Grade: 1.0) 
                                                   
10/2006 – 09/2009                           Bachelor of Science in Molecular Biotechnology at the  
                                                         University of Aachen (Grade: 1.6) 
 
04/2009 – 10/2009                           Bachelor Thesis at Fraunhofer Center for Molecular  
                                                         Biotechnology in Newark, Delaware (USA)  
                                                         Title: “Investigation of Heavy Chain Degradation  
                                                         of Plant-Produced Monoclonal Anti-PA Antibody“   
  (Grade: 1.3) 
 
 
 Scholarships 
 
  04/2009 – 09/2009                        Fraunhofer Stipend 
  10/2010 – 09/2011                        Bildungsfond Stipend of NRW 
 
 
 Qualifications/ Awards 
 
                                                         Biomedica Poster Award, 2013                                                          
                                                         Fraunhofer Innovation Award, 2012                                                       
                                                         Bayer Business Consulting Workshop, 2011 
                                                         FELASA B Certificate, 2012 
                                                         eBioscience Flow Cytometry Seminar Certificate, 2012 
 
 
